Note: Descriptions are shown in the official language in which they were submitted.
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
Recombinant nucleic acid construct
[001] The present invention is related to a recombinant nucleic acid
construct, a vector,
preferably an expression vector, comprising a recombinant nucleic acid
construct, a cell
comprising the recombinant nucleic acid construct and/or the vector, a
delivery vehicle
comprising the recombinant nucleic acid construct, a pharmaceutical
composition comprising
the recombinant nucleic acid construct, the recombinant nucleic acid construct
for use in a
method for the treatment and/or prevention of a disease, the recombinant
nucleic acid construct
for use in a method for restoring a cellular function of a cell, a method for
the treatment and/or
prevention of a disease and a method for restoring a cellular function of a
cell.
[002] Nucleic acid molecules serve various purposes in biological systems. One
out of
several purposes is to store genetic information, another one is to convey
genetic information
from deoxyribonucleic acid to the ribosome where such genetic information is
translated into
an amino acid sequence. The latter step involves the use of messenger
ribonucleic acid
(mRNA).
[003] mRNA shows a very basic design in eukaryotic cells and typically
comprises, in 5'->
3' direction, a Cap structure, a 5' untranslated region (5' UTR), a coding
sequence typically
starting with a AUG codon attached to a coding sequence (CDS) terminating with
a stop codon,
a 3' untranslated region (3' UTR) and a poly-A-tail.
[004] mRNA based therapy have been proposed as therapeutics since the
beginning of the
biotech. In principle, the administered mRNA sequence can cause a cell to make
a protein,
which in turn could directly treat a disease or could function as a vaccine;
more indirectly the
protein could interfere with an element of a pathway in such way that the
pathway is either
inhibited or stimulated, thereby treating or ameliorating a disease.
1
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[005] The problem underlying the present invention is the provision of a
recombinant nucleic
acid construct, preferably of an mRNA, whereby such recombinant nucleic acid
construct
allows for high expression of the coding sequence of the recombinant nucleic
acid construct.
[006] Another problem underlying the present invention is the provision of a
recombinant
nucleic acid construct, preferably of an mRNA, whereby such recombinant
nucleic acid
construct allows for the expression of the coding sequence of the recombinant
nucleic acid
construct in an endothelial cell.
[007] These and other problems underlying the present invention are solved by
the subject
matter of the attached independent claims; preferred embodiments may be taken
from the
attached dependent claims.
[008] Additionally, and more specifically, the problem underlying the present
invention is
solved in a first aspect, which is also the first embodiment of the first
aspect, by a recombinant
nucleic acid construct comprising in 5-> 3' direction
- a 5' UTR,
- a coding region coding for an effector molecule, and
- a 3' UTR,
wherein the 5' UTR is selected from the group comprising a 5' UTR of a gene
coding for MCP-
1 or a derivative thereof having a nucleotide identity of at least 85 %, a 5'
UTR of a gene coding
for RPL12s.c. or a derivative thereof having a nucleotide identity of at least
85 %, a 5' UTR of
a gene coding for Ang-2 or a derivative thereof having a nucleotide identity
of at least 85 %, a
5' UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide
identity of at
least 85 %, a 5' UTR of a gene coding for H3.3. or a derivative thereof having
a nucleotide
identity of at least 85 %, a 5' UTR of a gene coding for Galectin-9 or a
derivative thereof having
a nucleotide identity of at least 85 %, a 5' UTR of a gene coding for GADD34
or a derivative
thereof having a nucleotide identity of at least 85 %, a 5' UTR of a gene
coding for EDN1 or a
derivative thereof having a nucleotide identity of at least 85 %, a 5' UTR of
a gene coding for
HSP70m5 or a derivative thereof having a nucleotide identity of at least 85 %,
a 5' UTR of a
gene coding for E-selectin or a derivative thereof having a nucleotide
identity of at least 85 %
a 5' UTR of a gene coding for ICAM-1 or a derivative thereof having a
nucleotide identity of
at least 85 %, a 5' UTR of a gene coding for IL-6 or a derivative thereof
having a nucleotide
2
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
identity of at least 85 % and a 5' UTR of a gene coding for vWF or a
derivative thereof having
a nucleotide identity of at least 85 %;
wherein 3' UTR is selected from the group comprising a 3' UTR of a gene coding
for vWF or
a derivative thereof having a nucleotide identity of at least 85 %, a 3' UTR
of a gene coding for
MCP-1 or a derivative thereof having a nucleotide identity of at least 85 %, a
3' UTR of a gene
coding for RPL12s.c. or a derivative thereof having a nucleotide identity of
at least 85 %, a 3'
UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide
identity of at least
85 %, a 3' UTR of a gene coding for H3.3. or a derivative thereof having a
nucleotide identity
of at least 85 %, a 3' UTR of a gene coding for GADD34 or a derivative thereof
having a
nucleotide identity of at least 85 %, a 3' UTR of a gene coding for EDN1 or a
derivative thereof
having a nucleotide identity of at least 85 %, and a 3' UTR of a gene coding
for IL-6 or a
derivative thereof having a nucleotide identity of at least 85 %,
wherein the effector molecule is effective in restoring a cellular function of
a cell or is effective
in exercising a therapeutic effect in or on a cell, and
wherein the recombinant nucleic acid construct is different from a wild type
mRNA coding for
the effector molecule.
[009] In a second embodiment of the first aspect, which is also an embodiment
of the first
embodiment of the first aspect, the 5' UTR and the 3' UTR of the recombinant
construct are of
different origin, preferably are from different endogenous species.
[0010] In a third embodiment of the first aspect, which is also an embodiment
of the first and
second embodiment of the first aspect, the 5' UTR and the 3' UTR of the
recombinant construct
are of the same origin, preferably are from the same endogenous genes species.
[0011] In a fourth embodiment of the first aspect, which is also an embodiment
of the first,
second and third embodiment of the first aspect,
a) the 5' UTR is a 5' UTR of a gene coding for MCP-1 or a derivative
thereof having a
nucleotide identity of at least 85 %, and wherein the 3' UTR is selected from
the group
comprising a 3' UTR of a gene coding for vWF or a derivative thereof having a
nucleotide
3
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
identity of at least 85 %, a 3' UTR of a gene coding for HSP70 or a derivative
thereof having a
nucleotide identity of at least 85 %, a 3' UTR of a gene coding for RPL12s.c.
or a derivative
thereof having a nucleotide identity of at least 85 %, and a 3' UTR of a gene
coding for MCP-
1 or a derivative thereof having a nucleotide identity of at least 85 %.
b) the 5' UTR is a 5' UTR of a gene coding for RPL12s.c. or a derivative
thereof having a
nucleotide identity of at least 85 %, and wherein the 3' UTR is selected from
the group
comprising a 3' UTR of a gene coding for vWF or a derivative thereof having a
nucleotide
identity of at least 85 % , a 3' UTR of a gene coding for HSP70 or a
derivative thereof having
a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for
RPL12s.c. or a derivative
thereof having a nucleotide identity of at least 85 % and a 3' UTR of a gene
coding for MCP-1
or a derivative thereof having a nucleotide identity of at least 85 %,
c) the 5' UTR is a 5' UTR of a gene coding for ANG-2 or a derivative
thereof having a
nucleotide identity of at least 85 %, and wherein the 3' UTR is selected from
the group
comprising a 3' UTR of a gene coding for HSP70 or a derivative thereof having
a nucleotide
identity of at least 85 %, a 3' UTR of a gene coding for RPL12s.c. or a
derivative thereof having
a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for vWF or a
derivative thereof
having a nucleotide identity of at least 85 % and a 3' UTR of a gene coding
for MCP-1 or a
derivative thereof having a nucleotide identity of at least 85 %, or
d) the 5' UTR is a 5' UTR of a gene coding for HSP70 or a derivative
thereof having a
nucleotide identity of at least 85 %, and wherein the 3' UTR is selected from
the group
comprising a 3' UTR of a gene coding for HSP70 or a derivative thereof having
a nucleotide
identity of at least 85 %, a 3' UTR of a gene coding for RPL12s.c. or a
derivative thereof having
a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for vWF or a
derivative thereof
having a nucleotide identity of at least 85 % and a 3' UTR of a gene coding
for MCP-1 or a
derivative thereof having a nucleotide identity of at least 85 %.
[0012] In a fifth embodiment of the first aspect, which is also an embodiment
of the first,
second and third embodiment of the first aspect,
4
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
a) the 3'UTR is a 3' UTR of a gene coding for vWF or a derivative thereof
having a
nucleotide identity of at least 85 % and the 5' UTR is selected from the group
comprising a 5'
UTR of a gene coding for MCP-1 or a derivative thereof having a nucleotide
identity of at least
85 %, a 5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a
nucleotide
identity of at least 85 %, a 5' UTR of a gene coding for HSP70 or a derivative
thereof having a
nucleotide identity of at least 85 %, a 5' UTR of a gene coding for ANG-2 of a
derivative
thereof having a nucleotide identity of at least 85 %,
b) the 3'UTR is a 3' UTR of a gene coding for HSP70 or a derivative thereof
having a
nucleotide identity of at least 85 % and the 5' UTR is selected from the group
comprising a 5'
UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide
identity of at least
85 % a 5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a
nucleotide
identity of at least 85 %, a 5' UTR of a gene coding for ANG-2 of a derivative
thereof having
a nucleotide identity of at least 85 %, and a 5' UTR of a gene coding for MCP-
1 or a derivative
thereof having a nucleotide identity of at least 85 %,
c) the 3'UTR is a 3' UTR of a gene coding for RPL12s.c. or a derivative
thereof having a
nucleotide identity of at least 85 % and the 5' UTR is selected from the group
comprising a 5'
UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide
identity of at least
85 % a 5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a
nucleotide
identity of at least 85 %, a 5' UTR of a gene coding for ANG-2 of a derivative
thereof having
a nucleotide identity of at least 85 %, and a 5' UTR of a gene coding for MCP-
1 or a derivative
thereof having a nucleotide identity of at least 85 %,
or
d) the 3'UTR is a 3' UTR of a gene coding for MCP-1 or a derivative thereof
having a
nucleotide identity of at least 85 % and the 5' UTR is selected from the group
comprising a 5'
UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide
identity of at least
85 %, a 5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a
nucleotide
identity of at least 85 %, a 5' UTR of a gene coding for ANG-2 of a derivative
thereof having
a nucleotide identity of at least 85 %, and a 5' UTR of a gene coding for MCP-
1 or a derivative
thereof having a nucleotide identity of at least 85 %.
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0013] In a sixth embodiment of the first aspect, which is also an embodiment
of the first,
second, third, fourth and fifth embodiment of the first aspect, the construct
is one selected from
the group comprising
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for MCP-1 or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
vWF or a derivative thereof having a nucleotide identity of at least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for RPL12s.c. or
a derivative
thereof having a nucleotide identity of at least 85 %, and the 3' UTR is a 3'
UTR of a gene
coding for vWF or a derivative thereof having a nucleotide identity of at
least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for MCP-1 or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
MCP-1 or a derivative thereof having a nucleotide identity of at least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for ANG-2 or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
vWF or a derivative thereof having a nucleotide identity of at least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for RPL12s.c. or
a derivative
thereof having a nucleotide identity of at least 85 %, and the 3' UTR is a 3'
UTR of a gene
coding for RPL12s.c. or a derivative thereof having a nucleotide identity of
at least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for HSP70 or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
HSP70 or a derivative thereof having a nucleotide identity of at least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for H3.3. or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
H3.3. or a derivative thereof having a nucleotide identity of at least 85 %,
and
6
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for Galectin 9 or
a derivative
thereof having a nucleotide identity of at least 85 %, and the 3' UTR is a 3'
UTR of a gene
coding for Galectin 9 or a derivative thereof having a nucleotide identity of
at least 85 %.
[0014] In a seventh embodiment of the first aspect, which is also an
embodiment of the first,
second, third, fourth, fifth and sixth embodiment of the first aspect, the
construct comprises a
poly-A tail, preferably at the 3' terminal end of the recombinant nucleic acid
construct.
[0015] In an eighth embodiment of the first aspect, which is also an
embodiment of the first,
second, third, fourth, fifth, sixth and seventh embodiment of the first
aspect, the construct
comprises a CAP structure, preferably at the 5' terminal end of the
recombinant nucleic acid
construct.
[0016] In a ninth embodiment of the first aspect, which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh and eighth embodiment of the
first aspect, the
construct comprises a IRES (internal ribosomal entry site) sequence,
preferably at the 5'
terminal end of the recombinant nucleic acid construct.
[0017] In a tenth embodiment of the first aspect, which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth and ninth embodiment of
the first aspect, the
construct comprises nucleic acid sequence coding for a signal peptide,
preferably the signal
peptide is in-frame with nucleic acid sequence coding for a signal peptide and
is arranged
between the 5' UTR and the coding region coding for an effector molecule.
[0018] In an eleventh embodiment of the first aspect, which is also an
embodiment of the
tenth embodiment of the first aspect, the signal peptide allows secretion of
the effector
molecule.
[0019] In a 12th embodiment of the first aspect, which is also an embodiment
of the tenth and
the eleventh embodiment of the first aspect, the nucleotide sequence coding
for a signal peptide
is selected from the group comprising a nucleotide sequence coding for a
signal peptide of
MCP-1 or a derivative thereof having a nucleotide identity of at least 85 %,
nucleotide sequence
coding for a signal peptide of IL-6 or a derivative thereof having a
nucleotide identity of at
least 85 %, a nucleotide sequence coding for a signal peptide of Ang-2 or a
derivative thereof
7
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
having a nucleotide identity of at least 85 %, and a nucleotide sequence
coding for a signal
peptide of Ang-1 or a derivative thereof having a nucleotide identity of at
least 85 %.
[0020] In a13th embodiment of the first aspect, which is also an embodiment of
the first, second,
third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh and 12th
embodiment of the first
aspect, the cell a cellular function of which is restored and/or the cell in
or on which a
therapeutic effect is exercised is an endothelial cell, preferably a vascular
endothelial cell, more
preferably the vascular endothelial cell is a microvascular endothelial cell.
[0021] In 14th embodiment of the first aspect, which is also an embodiment of
the first, second,
third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, 12th and
13" embodiment of
the first aspect, the cellular function is one which can be restored by an
effector molecule having
anti-permeability effect of endothelial cells, an anti-vascular leakage
effect, an anti-apoptotic
effect of endothelial cells or an anti-inflammatory effect of endothelial
cells or an anti-stress
response effect, preferably the effect is linked to or associated with the Tie-
2 signalling
pathway, VEGF-receptor pathway, NOTCH signalling pathway, P13-kinase pathway,
eNOS
signalling pathway, sirtuin-dependent metabolic and energy homeostasis
pathway, oxidative
stress pathway, shear stress response pathway, ET-1 signal transduction
pathway, NO-mediated
signal transduction pathway, and mechanochemical transduction pathway.
[0022] More specifically, the problem underlying the present invention is
solved in a second
aspect, which is also a first embodiment of the second aspect, by a
recombinant nucleic acid
construct comprising in 5-> 3' direction
- a 5' non-translated region,
- a coding region coding for an effector molecule, and
- a 3' non-translated region,
wherein the effector molecule is effective in restoring a cellular function of
a cell, for use in a
method for the treatment and/or prevention of a disease, wherein the effector
molecule is
expressed by an endothelial cell. In an embodiment and as preferably used
herein restoring a
cellular function comprises and, respectively, encompasses killing of a cell,
more preferably
killing of tumor endothelial cells and/or tumor cells; in another embodiment
and as preferably
used herein, restoring cellular function comprises and, respectively,
encompasses
neoangiogenesis, more preferably neoangiogenesis in case of vascular diseases.
8
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0023] In a second embodiment of the second aspect which is also an embodiment
of the first
embodiment of the second aspect, the treatment and/or prevention of a disease
involves
restoration of the cellular function of a cell.
[0024] More specifically, the problem underlying the present invention is
solved in a third
aspect, which is also a first embodiment of the third aspect, by a recombinant
nucleic acid
construct comprising in 5'-> 3' direction
- a 5' non-translated region,
- a coding region coding for an effector molecule, and
- a 3' non-translated region,
wherein the effector molecule is effective in restoring a cellular function of
a cell, for use
in a method for restoring the cellular function of a cell, wherein the
effector molecule is
expressed by an endothelial cell.
[0025] More specifically, the problem underlying the present invention is
solved in a
fourth aspect, which is also a first embodiment of the fourth aspect, by a
recombinant
nucleic acid construct comprising in 5'-> 3' direction
- a 5' non -translated region,
- a coding region coding for an effector molecule, and
- a 3' non-translated region,
wherein the effector molecule is effective in exercising a therapeutic effect
in or on a cell,
for use in a method for the treatment and/or prevention of a disease, wherein
the effector
molecule is expressed by an endothelial cell.
[0026] In a second embodiment of the fourth aspect which is also an embodiment
of the first
embodiment of the fourth aspect, the treatment and/or prevention of a disease
involves
restoration of a cellular function of a cell.
9
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0027] More specifically, the problem underlying the present invention is
solved in a fifth
aspect, which is also a first embodiment of the fifth aspect, by a recombinant
nucleic acid
construct comprising in 5'-> 3' direction
- a 5' non -translated region,
- a coding region coding for an effector molecule, and
- a 3' non-translated region,
wherein the effector molecule is effective in exercising a therapeutic effect
in or on a cell,
for use of in a method for restoring a cellular function of a cell, wherein
the effector
molecule is expressed by an endothelial cell.
[0028] In a third embodiment of the second aspect which is also an embodiment
of the first
and second embodiment of the second aspect, in a second embodiment of the
third aspect which
is also an embodiment of the first embodiment of the third aspect, in a third
embodiment of the
fourth aspect which is also an embodiment of the first and second embodiment
of the fourth
aspect, and in a second embodiment of the fifth aspect which is also an
embodiment of the first
embodiment of the fifth aspect, the effector molecule is expressed in the
method by an
endothelial cell.
[0029] In a fourth embodiment of the second aspect which is also an embodiment
of the first,
second and third embodiment of the second aspect, in a third embodiment of the
third aspect
which is also an embodiment of the first and the second embodiment of the
third aspect, in a
fourth embodiment of the fourth aspect which is also an embodiment of the
first, second and
third embodiment of the fourth aspect, and in a third embodiment of the fifth
aspect which is
also an embodiment of the first and second embodiment of the fifth aspect, the
endothelial cell
is a vascular endothelial cell, preferably the vascular endothelial cell is a
microvascular
endothelial cell.
[0030] In a fifth embodiment of the second aspect which is also an embodiment
of the first,
second, third and fourth embodiment of the second aspect, in a fourth
embodiment of the third
aspect which is also an embodiment of the first, second and third embodiment
of the third
aspect, in a fifth embodiment of the fourth aspect which is also an embodiment
of the first,
second, third and fourth embodiment of the fourth aspect, and in a fourth
embodiment of the
fifth aspect which is also an embodiment of the first, second and third
embodiment of the fifth
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
aspect, the endothelial cell is a non-dividing endothelial cell, a non-
proliferating endothelial
cell or a resting endothelial cell. In an embodiment thereof and as preferably
used herein the
endothelial is a vascular endothelial cell, a lymphatic endothelial cells, an
endothelial stem cell
(ESC) or an endothelial progenitor cells (EPC).
[0031] In a sixth embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth and fifth embodiment of the second aspect, in a fifth
embodiment of the
third aspect which is also an embodiment of the first, second, third and
fourth embodiment of
the third aspect, in a sixth embodiment of the fourth aspect which is also an
embodiment of the
first, second, third, fourth and fifth embodiment of the fourth aspect, and in
a fifth embodiment
of the fifth aspect which is also an embodiment of the first, second, third
and fourth embodiment
of the fifth aspect, the endothelial cell is a senescent endothelial cell.
[0032] In a seventh embodiment of the second aspect which is also an
embodiment of the
first, second, third, fourth, fifth and sixth embodiment of the second aspect,
in a sixth
embodiment of the third aspect which is also an embodiment of the first,
second, third, fourth
and fifth embodiment of the third aspect, in a seventh embodiment of the
fourth aspect which
is also an embodiment of the first, second, third, fourth, fifth and sixth
embodiment of the fourth
aspect, and in a sixth embodiment of the fifth aspect which is also an
embodiment of the first,
second, third, fourth and fifth embodiment of the fifth aspect, the
endothelial cell is impaired
by age and/or showing stress-related defects.
[0033] In an eighth embodiment of the second aspect which is also an
embodiment of the first,
second, third, fourth, fifth, sixth and seventh embodiment of the second
aspect, in a seventh
embodiment of the third aspect which is also an embodiment of the first,
second, third, fourth,
fifth and sixth embodiment of the third aspect, in an eighth embodiment of the
fourth aspect
which is also an embodiment of the first, second, third, fourth, fifth, sixth
and seventh
embodiment of the fourth aspect, and in a seventh embodiment of the fifth
aspect which is also
an embodiment of the first, second, third, fourth, fifth and sixth embodiment
of the fifth aspect,
the recombinant nucleic acid construct additionally comprises one element
selected from the
group comprising a cap structure, an IRES sequence, a further start codon
providing sequence,
a nucleic acid sequence coding for a signal peptide and a poly-A tail.
11
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0034] In a ninth embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh and eighth embodiment of the
second aspect, in an
eighth embodiment of the third aspect which is also an embodiment of the
first, second, third,
fourth, fifth, sixth and seventh embodiment of the third aspect, in a ninth
embodiment of the
fourth aspect which is also an embodiment of the first, second, third, fourth,
fifth, sixth, seventh
and eighth embodiment of the fourth aspect, and in an eighth embodiment of the
fifth aspect
which is also an embodiment of the first, second, third, fourth, fifth, sixth
and seventh
embodiment of the fifth aspect,
wherein the recombinant nucleic acid construct is one selected from the group
comprising in
5'-> 3' direction
a) - a 5' non -translated region,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
b) - a 5' non -translated region,
- a further start codon providing sequence,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
c) - a cap structure,
- a 5' non -translated region,
- a coding region coding for an effector molecule, and
- a 3' non-translated region;
d) - a cap structure,
- a 5' non -translated region,
- a further start codon providing sequence,
- a coding region coding for an effector molecule, and
- a 3' non-translated region;
e) - an IRES sequence,
- a 5' non -translated region,
- a coding region coding for an effector molecule, and
- a 3' non-translated region;
12
CA 03108670 2021-02-03
WO 2020/030672
PCT/EP2019/071173
0 - an IRES sequence,
- a 5' non -translated region,
- a further start codon providing sequence,
- a coding region coding for an effector molecule, and
- a 3' non-translated region;
g) - a cap structure,
- a 5' non -translated region,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
h) - a cap structure,
- a 5' non -translated region,
- a further start codon providing sequence,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
i) - an IRES sequence,
- a 5' non -translated region,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
j) - an IRES sequence,
- a 5' non -translated region,
- a further start codon providing sequence,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
k) - a 5' non -translated region,
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
1) - a 5' non -translated region,
- a further start codon providing sequence,
13
CA 03108670 2021-02-03
WO 2020/030672
PCT/EP2019/071173
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
m) - a cap structure,
- a 5' non -translated region,
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule, and
- a 3' non-translated region;
- a cap structure
- a 5' non -translated region,
- a further start codon providing sequence,
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule, and
- a 3' non-translated region;
o) - an IRES sequence,
- a 5' non -translated region,
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule, and
- a 3' non-translated region;
13) - an IRES sequence,
- a 5' non -translated region,
- a further start codon providing sequence,
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule, and
- a 3' non-translated region;
q) - a cap structure,
- a 5' non -translated region,
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
r) - a cap structure,
14
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
- a 5' non -translated region,
- a further start codon providing sequence,
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail;
s) - an IRES sequence,
- a 5' non -translated region,
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail; and
t) - an IRES sequence,
- a 5' non -translated region,
- a further start codon providing sequence,
- a nucleic acid sequence coding for a signal peptide,
- a coding region coding for an effector molecule,
- a 3' non-translated region, and
- a poly-A tail.
[0035] In a tenth embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth and ninth embodiment of
the second aspect,
in an ninth embodiment of the third aspect which is also an embodiment of the
first, second,
third, fourth, fifth, sixth, seventh and eighth embodiment of the third
aspect, in a tenth
embodiment of the fourth aspect which is also an embodiment of the first,
second, third, fourth,
fifth, sixth, seventh, eighth and ninth embodiment of the fourth aspect, and
in an ninth
embodiment of the fifth aspect which is also an embodiment of the first,
second, third, fourth,
fifth, sixth, seventh and eighth embodiment of the fifth aspect, the
recombinant nucleic acid
comprises in 5' -> 3' direction
a cap structure,
a 5' non -translated region,
a nucleic acid sequence coding for a signal peptide,
a coding region coding for an effector molecule,
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
a 3' non-translated region, and
a poly-A tail.
[0036] In an eleventh embodiment of the second aspect which is also an
embodiment of the
first, second, third, fourth, fifth, sixth, seventh, eighth, ninth and tenth
embodiment of the
second aspect, in a tenth embodiment of the third aspect which is also an
embodiment of the
first, second, third, fourth, fifth, sixth, seventh, eighth and ninth
embodiment of the third aspect,
in an eleventh embodiment of the fourth aspect which is also an embodiment of
the first, second,
third, fourth, fifth, sixth, seventh, eighth, ninth and tenth embodiment of
the fourth aspect, and
in a tenth embodiment of the fifth aspect which is also an embodiment of the
first, second, third,
fourth, fifth, sixth, seventh, eighth and ninth embodiment of the fifth
aspect, the recombinant
nucleic acid comprises in 5' -> 3' direction
an IRES sequence,
a 5' non -translated region,
a nucleic acid sequence coding for a signal peptide,
a coding region coding for an effector molecule,
a 3' non-translated region, and
a poly-A tail.
[0037] In a 12th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth and
eleventh embodiment of the
second aspect, in an eleventh embodiment of the third aspect which is also an
embodiment of
the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth and
tenth embodiment of the
third aspect, in a 12th embodiment of the fourth aspect which is also an
embodiment of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth and
eleventh embodiment of the
fourth aspect, and in an eleventh embodiment of the fifth aspect which is also
an embodiment
of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth and
tenth embodiment of
the fifth aspect, recombinant nucleic acid comprises in 5' -> 3' direction
a cap structure,
a 5' non -translated region,
a further start codon providing sequence,
a nucleic acid sequence coding for a signal peptide,
16
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
a coding region coding for an effector molecule,
a 3' non-translated region, and
a poly-A tail.
[0038] In a 13th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh
and 12th embodiment
of the second aspect, in a 12th embodiment of the third aspect which is also
an embodiment of
the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth
and eleventh embodiment
of the third aspect, in a 13th embodiment of the fourth aspect which is also
an embodiment of
the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh and 12th
embodiment of the fourth aspect, and in an 12th embodiment of the fifth aspect
which is also an
embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth,
ninth, tenth and
eleventh embodiment of the fifth aspect, the recombinant nucleic acid
comprises in 5' -> 3'
direction
an IRES sequence,
a 5' non -translated region,
a further start codon providing sequence,
a nucleic acid sequence coding for a signal peptide,
a coding region coding for an effector molecule,
a 3' non-translated region, and
a poly-A tail.
[0039] In a 14th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th and 13th
embodiment of the second aspect, in a 13th embodiment of the third aspect
which is also an
embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth,
ninth, tenth, eleventh
and 12th embodiment of the third aspect, in a 14th embodiment of the fourth
aspect which is also
an embodiment of the first, second, third, fourth, fifth, sixth, seventh,
eighth, ninth, tenth,
eleventh, 12th and 13th embodiment of the fourth aspect, and in an 13th
embodiment of the fifth
aspect which is also an embodiment of the first, second, third, fourth, fifth,
sixth, seventh,
eighth, ninth, tenth, eleventh and 12th embodiment of the fifth aspect, the
further start codon
providing sequence is in-frame with the coding region coding for an effector
molecule.
17
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0040] In a 15th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th and 14th
embodiment of the second aspect, in a 14th embodiment of the third aspect
which is also an
embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth,
ninth, tenth, eleventh,
12" and 13th embodiment of the third aspect, in a 15" embodiment of the fourth
aspect which
is also an embodiment of the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth,
eleventh, 12th, 13th and 14th embodiment of the fourth aspect, and in an 14th
embodiment of the
fifth aspect which is also an embodiment of the first, second, third, fourth,
fifth, sixth, seventh,
eighth, ninth, tenth, eleventh 12" and 13th embodiment of the fifth aspect,
the 5' non -translated
region is a 5' UTR.
[0041] In a 16th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th and 15th
embodiment of the second aspect, in a 15th embodiment of the third aspect
which is also an
embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth,
ninth, tenth, eleventh,
12th, 13th and 14th embodiment of the third aspect, in a 16th embodiment of
the fourth aspect
which is also an embodiment of the first, second, third, fourth, fifth, sixth,
seventh, eighth,
ninth, tenth, eleventh, 12th, 13th, 14th and , ,-th
ID embodiment of the fourth aspect, and in an 15th
embodiment of the fifth aspect which is also an embodiment of the first,
second, third, fourth,
fifth, sixth, seventh, eighth, ninth, tenth, eleventh 12th, 13th and 14th
embodiment of the fifth
aspect, the 5' non-translated region is from a eukaryotic organism, preferably
a mammalian
organism, more preferably a mammalian organism selected from the group
comprising human,
non-human primate such as cynomolgus, chimpanzee rhesus monkey, rat and mouse.
In an
alternative embodiment the 5' non-translated region is from a viral gene,
preferably the virus is
a virus capable of infecting a eukaryotic organism.
[0042] In a 17th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th and
16th embodiment of the second aspect, in a 16th embodiment of the third aspect
which is also
an embodiment of the first, second, third, fourth, fifth, sixth, seventh,
eighth, ninth, tenth,
eleventh, 12th, 13th, 14th and 15th embodiment of the third aspect, in a 17th
embodiment of the
fourth aspect which is also an embodiment of the first, second, third, fourth,
fifth, sixth, seventh,
eighth, ninth, tenth, eleventh, 12th, 13th, 14th, 15th and 16th embodiment of
the fourth aspect, and
in an 16th embodiment of the fifth aspect which is also an embodiment of the
first, second,
18
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh 12th,
oth,i A th
4 and 15th
embodiment of the fifth aspect, the 5' UTR is selected from the group
comprising a 5' UTR of
a gene coding for MCP-1 or a derivative thereof having a nucleotide identity
of at least 85 %,
a 5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a
nucleotide identity of
at least 85 %, a 5' UTR of a gene coding for Ang-2 or a derivative thereof
having a nucleotide
identity of at least 85 %, a 5' UTR of a gene coding for HSP70 or a derivative
thereof having a
nucleotide identity of at least 85 %, a 5' UTR of a gene coding for H3.3. or a
derivative thereof
having a nucleotide identity of at least 85 %, and a 5' UTR of a gene coding
for Galectin-9 or
a derivative thereof having a nucleotide identity of at least 85 %.
[0043] In an 18th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, rth,
J 16th
and 17th embodiment of the second aspect, in a 17th embodiment of the third
aspect which is
also an embodiment of the first, second, third, fourth, fifth, sixth, seventh,
eighth, ninth, tenth,
eleventh, 12th, 13th, 1 A4 th,
15th and 16th embodiment of the third aspect, in an 18th embodiment
of the fourth aspect which is also an embodiment of the first, second, third,
fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, 12th, 13th, 14th, 15th, 16th and 17th
embodiment of the
fourth aspect, and in an 17th embodiment of the fifth aspect which is also an
embodiment of
the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh 12th, 13th, 14th
and 15th, 16th embodiment of the fifth aspect, the 3' non-translated region is
a 3' -UTR.
[0044] In a 19th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th,
16th, 17th and 18th embodiment of the second aspect, in an 18th embodiment of
the third aspect
which is also an embodiment of the first, second, third, fourth, fifth, sixth,
seventh, eighth,
ninth, tenth, eleventh, 12th, 13th, 14th ,
15th, 16th and 17th embodiment of the third aspect, in a
19th embodiment of the fourth aspect which is also an embodiment of the first,
second, third,
fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, 12th, 13th,
14th, 15th, 16th , 17th and
18th embodiment of the fourth aspect, and in an 18th embodiment of the fifth
aspect which is
also an embodiment of the first, second, third, fourth, fifth, sixth, seventh,
eighth, ninth, tenth,
eleventh 12th, oth14,, A th
and 15th, 16th, 17th embodiment of the fifth aspect, the 3' non-translated
region is from a eukaryotic organism, preferably a mammalian organism, more
preferably a
mammalian organism selected from the group comprising human, non-human primate
such as
cynomolgus, chimpanzee rhesus monkey, rat and mouse. In an alternative
embodiment the 5'
19
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
non-translated region is from a viral gene, preferably the virus is a virus
capable of infecting a
eukaryotic organism.
[0045] In a 20th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12", 13th, 14", 15th,
16", 17th, 18th and 19th embodiment of the second aspect, in a 19th embodiment
of the third
aspect which is also an embodiment of the first, second, third, fourth, fifth,
sixth, seventh,
eighth, ninth, tenth, eleventh, 12th, 13th, 14th, 15tn, 1,--0th,
17th and 18th embodiment of the third
aspect, in a 20" embodiment of the fourth aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12", 13th, 14th, 15th,
1to,th,
17th, 18th and 19th embodiment of the fourth aspect, and in a 19" embodiment
of the fifth
aspect which is also an embodiment of the first, second, third, fourth, fifth,
sixth, seventh,
eighth, ninth, tenth, eleventh 12", 13th,14th, 15tn, 1,--0th,
17th and 18th embodiment of the fifth
aspect, the 3' UTR is selected from the group comprising a 3' UTR of a gene
coding for vWF
or a derivative thereof having a nucleotide identity of at least 85 %, a 3'
UTR of a gene coding
for MCP-1 or a derivative thereof having a nucleotide identity of at least 85
%, a 3' UTR of a
gene coding for RPL12s.c. or a derivative thereof having a nucleotide identity
of at least 85 %,
a 3' UTR of a gene coding for HSP70 or a derivative thereof having a
nucleotide identity of at
least 85 %, and a 3' UTR of a gene coding for H3.3. or a derivative thereof
having a nucleotide
identity of at least 85 %.
[0046] In a 21st embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12", 13th, 14", 15th,
16th, rth,
/ 18th, 19th and 20" embodiment of the second aspect, in a 20th
embodiment of the third
aspect which is also an embodiment of the first, second, third, fourth, fifth,
sixth, seventh,
eighth, ninth, tenth, eleventh, 12th, 13tn, 14th, 15th, 1,--0th,
17th, 18th and 19th embodiment of the
third aspect, in a 21st embodiment of the fourth aspect which is also an
embodiment of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, rth,
J 16th
, rth,
/ 18th 19th and 20" embodiment of the fourth aspect, and in a 20th
embodiment of the fifth
aspect which is also an embodiment of the first, second, third, fourth, fifth,
sixth, seventh,
eighth, ninth, tenth, eleventh 12th, 13th 14th 15th,
16th, 17th, 18th and 19" embodiment of the fifth
aspect, the 5' UTR and 3' UTR of the recombinant nucleic acid construct are of
different origin,
preferably are from different species.
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0047] In a 22nd embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th,
1,-th,
17th, 18th, 19th, 20th and 21st embodiment of the second aspect, in a 21st
embodiment of the
third aspect which is also an embodiment of the first, second, third, fourth,
fifth, sixth, seventh,
eighth, ninth, tenth, eleventh, 12th, 13th, 14th, 15th, 16th, 17th, 1,-,6th,
19th and 20th embodiment of
the third aspect, in a 22nd embodiment of the fourth aspect which is also an
embodiment of the
first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh, 12th, 13th, 14th,
15th, 10+ ,th ,
17th, 18th 19th, 20th and 21st embodiment of the fourth aspect, and in a 21st
embodiment
of the fifth aspect which is also an embodiment of the first, second, third,
fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh 12th, 13th,14th 15th, 16th, 17th,
18th, 19th and 20th
embodiment of the fifth aspect, the 5' UTR and 3' UTR of the recombinant
nucleic acid
construct are of the same origin, preferably are from the same species.
[0048] In a 23rd embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th,
, --th,
in
17th, 18th, 19th, 20th, 21stand 22ndembodiment of the second aspect, in a 22nd
embodiment
of the third aspect which is also an embodiment of the first, second, third,
fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, 12th, 13th, 14, .th,
15th, 16th, 17th, 18th,19th 20th and 21st
embodiment of the third aspect, in a 23rd embodiment of the fourth aspect
which is also an
embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth,
ninth, tenth, eleventh,
12th, 13th, 14, Atli,
15th, 16th , 17th, 18th 19th and 20th, 21st and 22nd embodiment of the fourth
aspect,
and in a 22nd embodiment of the fifth aspect which is also an embodiment of
the first, second,
third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh 12th,
13th,14th 15th, 16th, 17th,
lei, 19, µ-sth,
20th and 21st embodiment of the fifth aspect,
a) the
5' UTR is a 5' UTR of a gene coding for MCP-1 or a derivative thereof having a
nucleotide identity of at least 85 %, and wherein the 3' UTR is selected from
the group
comprising a 3' UTR of a gene coding for vWF or a derivative thereof having a
nucleotide
identity of at least 85 %, a 3' UTR of a gene coding for HSP70 or a derivative
thereof having a
nucleotide identity of at least 85 %, a 3' UTR of a gene coding for RPL12s.c.
or a derivative
thereof having a nucleotide identity of at least 85 %, and a 3' UTR of a gene
coding for MCP-
1 or a derivative thereof having a nucleotide identity of at least 85 %.
21
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
b) the 5' UTR is a 5' UTR of a gene coding for RPL12s.c. or a derivative
thereof having a
nucleotide identity of at least 85 %, and wherein the 3' UTR is selected from
the group
comprising a 3' UTR of a gene coding for vWF or a derivative thereof having a
nucleotide
identity of at least 85 %, a 3' UTR of a gene coding for HSP70 or a derivative
thereof having a
nucleotide identity of at least 85 %, a 3' UTR of a gene coding for RPL12s.c.
or a derivative
thereof having a nucleotide identity of at least 85 %, and a 3' UTR of a gene
coding for MCP-
1 or a derivative thereof having a nucleotide identity of at least 85 %,
c) the 5' UTR is a 5' UTR of a gene coding for HSP70 or a derivative
thereof having a
nucleotide identity of at least 85 %, and wherein the 3' UTR is selected from
the group
comprising a 3' UTR of a gene coding for HSP70 or a derivative thereof having
a nucleotide
identity of at least 85 %, a 3' UTR of a gene coding for RPL12s.c. or a
derivative thereof having
a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for vWF or a
derivative thereof
having a nucleotide identity of at least 85 % and a 3' UTR of a gene coding
for MCP-1 or a
derivative thereof having a nucleotide identity of at least 85 %, or
d) the 5' UTR is a 5' UTR of a gene coding for ANG-2 or a derivative
thereof having a
nucleotide identity of at least 85 %, and wherein the 3' UTR is selected from
the group
comprising a 3' UTR of a gene coding for HSP70 or a derivative thereof having
a nucleotide
identity of at least 85 %, a 3' UTR of a gene coding for RPL12s.c. or a
derivative thereof having
a nucleotide identity of at least 85 %, a 3' UTR of a gene coding for vWF or a
derivative thereof
having a nucleotide identity of at least 85 % and a 3' UTR of a gene coding
for MCP-1 or a
derivative thereof having a nucleotide identity of at least 85 %.
[0049] In a 24th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th,
16th, 17th, 18th, rth,
V 20th, 21st, 22nd and 23rd embodiment of the second aspect, in a 23rd
embodiment of the third aspect which is also an embodiment of the first,
second, third, fourth,
fifth, sixth, seventh, eighth, ninth, tenth, eleventh, 12th, 13th, 14th
15th, 16th, 17th, 18th, 19th, 20th,
21st and 22nd embodiment of the third aspect, in a 24" embodiment of the
fourth aspect which
is also an embodiment of the first, second, third, fourth, fifth, sixth,
seventh, eighth, ninth, tenth,
eleventh, 12th, 13th, 14th, 15th, 16th , 17th, 18th , 19th, 20th, 215t, 22nd
and 23rd embodiment of the
fourth aspect, and in a 23rd embodiment of the fifth aspect which is also an
embodiment of the
22
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh 12th, 13th,14th 15th,
16th, 17th, 18th, 19th, 20th, 21st and 22nd embodiment of the fifth aspect,
a) 3'UTR is a 3' UTR of a gene coding for vWF or a derivative thereof
having a nucleotide
identity of at least 85 % and the 5' UTR is selected from the group comprising
a 5' UTR of a
gene coding for MCP-1 or a derivative thereof having a nucleotide identity of
at least 85 %, a
5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a
nucleotide identity of
at least 85 %, a 5' UTR of a gene coding for HSP70 or a derivative thereof
having a nucleotide
identity of at least 85 %, and a 5' UTR of a gene coding for ANG-2 of a
derivative thereof
having a nucleotide identity of at least 85 %, and,
b) 3'UTR is a 3' UTR of a gene coding for HSP70 or a derivative thereof
having a
nucleotide identity of at least 85 % and the 5' UTR is selected from the group
comprising a 5'
UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide
identity of at least
85 % a 5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a
nucleotide
identity of at least 85 %, a 5' UTR of a gene coding for ANG-2 of a derivative
thereof having
a nucleotide identity of at least 85 %, and a 5' UTR of a gene coding for MCP-
1 or a derivative
thereof having a nucleotide identity of at least 85 %,
c) 3'UTR is a 3' UTR of a gene coding for RPL12s.c. or a derivative thereof
having a
nucleotide identity of at least 85 % and the 5' UTR is selected from the group
comprising a 5'
UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide
identity of at least
85 % a 5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a
nucleotide
identity of at least 85 %, a 5' UTR of a gene coding for ANG-2 of a derivative
thereof having
a nucleotide identity of at least 85 %, and a 5' UTR of a gene coding for MCP-
1 or a derivative
thereof having a nucleotide identity of at least 85 %,
or
d) 3'UTR is a 3' UTR of a gene coding for MCP-1 or a derivative thereof
having a
nucleotide identity of at least 85 % and the 5' UTR is selected from the group
comprising a 5'
UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide
identity of at least
85 %, a 5' UTR of a gene coding for RPL12s.c. or a derivative thereof having a
nucleotide
identity of at least 85 %, a 5' UTR of a gene coding for ANG-2 of a derivative
thereof having
23
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
a nucleotide identity of at least 85 %, and a 5' UTR of a gene coding for MCP-
1 or a derivative
thereof having a nucleotide identity of at least 85 %.
[0050] In a 25th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th,
16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd and 24th embodiment of the
second aspect, in a 24th
embodiment of the third aspect which is also an embodiment of the first,
second, third, fourth,
fifth, sixth, seventh, eighth, ninth, tenth, eleventh, 12th, 13th, 14th, 15th,
16th, 17th, o , ,-,th,
1
19th, 20th:
21st, 22nd and 23rd embodiment of the third aspect, in a 25th embodiment of
the fourth aspect
which is also an embodiment of the first, second, third, fourth, fifth, sixth,
seventh, eighth,
ninth, tenth, eleventh, 12th, 13th, 14th, 15th, 16th , 17th, 18th , 19th,
20th, 21st, 22nd, 23rd and 24th
embodiment of the fourth aspect, and in a 24th embodiment of the fifth aspect
which is also an
embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth,
ninth, tenth, eleventh
12t1, 13th,14th 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd and 23rd
embodiment of the fifth aspect,
the construct is one selected from the group comprising
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for MCP-1 or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
vWF or a derivative thereof having a nucleotide identity of at least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for RPL12s.c. or
a derivative
thereof having a nucleotide identity of at least 85 %, and the 3' UTR is a 3'
UTR of a gene
coding for vWF or a derivative thereof having a nucleotide identity of at
least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for MCP-1 or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
MCP-1 or a derivative thereof having a nucleotide identity of at least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for ANG-2 or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
vWF or a derivative thereof having a nucleotide identity of at least 85 %,
24
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for RPL12s.c. or
a derivative
thereof having a nucleotide identity of at least 85 %, and the 3' UTR is a 3'
UTR of a gene
coding for RPL12s.c. or a derivative thereof having a nucleotide identity of
at least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for HSP70 or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
HSP70 or a derivative thereof having a nucleotide identity of at least 85 %,
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for H3.3. or a
derivative thereof
having a nucleotide identity of at least 85 %, and the 3' UTR is a 3' UTR of a
gene coding for
H3.3. or a derivative thereof having a nucleotide identity of at least 85 %,
or
a construct, wherein the 5' UTR is a 5' UTR of a gene coding for Galectin 9 or
a derivative
thereof having a nucleotide identity of at least 85 %, and the 3' UTR is a 3'
UTR of a gene
coding for Galectin 9 or a derivative thereof having a nucleotide identity of
at least 85 %.
[0051] In a 26th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12", 13th, 14", 15th,
16th, 17th, 18th, 19th 20t.. h ,.., , 21st, 22nd, Li ,,,srd,
24th and 25th embodiment of the second aspect, in a
25" embodiment of the third aspect which is also an embodiment of the first,
second, third,
fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, 12th, 13th,
14th, 15th, 16th, 17th, 18th,
19th, 20th, 21st, LL ,,,,nd,
23rd and 24th embodiment of the third aspect, in a 26th embodiment of the
fourth aspect which is also an embodiment of the first, second, third, fourth,
fifth, sixth, seventh,
eighth, ninth, tenth, eleventh, 12th, 13th, 14th, 15th, 16th , 17th, 18th ,
19th, 20th, 21st , 22nd, and 23rd,
24" and 25th embodiment of the fourth aspect, and in a 25" embodiment of the
fifth aspect
which is also an embodiment of the first, second, third, fourth, fifth, sixth,
seventh, eighth,
ninth, tenth, eleventh 12th, 13th,14th 15th, 16th, 17th, 18th, 19th, 20th,
21st, LL ,,,sind,
23rd and 24th
embodiment of the fifth aspect, the construct comprises a poly-A tail.
[0052] In a 27" embodiment of the second aspect which is also an embodiment of
the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12", 13th, 14", 15th,
16th, 17th, 116+ nth,
19th, 20th, 21st, 22nd, 23rd, n Atli,
24 25th and 26th embodiment of the second
aspect, in
a 26th embodiment of the third aspect which is also an embodiment of the
first, second, third,
fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, 12", 13th,
14th, 15th, 16th, 17th, 18th,
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
19th, 20th, 21st, 22nd, ,,,srd ,
Li
24th and 25t1i embodiment of the third aspect, in a 27th embodiment of
the fourth aspect which is also an embodiment of the first, second, third,
fourth, fifth, sixth,
seventh, eighth, ninth, tenth, eleventh, 12th, 13", 14", ID , ,th,
16th , 17th, 18th , 19th, 20th, 21st , 22nd,
23rd, 24th, 25th and 26th embodiment of the fourth aspect, and in a 26th
embodiment of the fifth
aspect which is also an embodiment of the first, second, third, fourth, fifth,
sixth, seventh,
eighth, ninth, tenth, eleventh 12th, 13th,14th 15th, 16th, 1 / , -,th,
18th, 19th, 20th, 21st, 22nd, 23rd, 24th
and 25thembodiment of the fifth aspect, the construct comprises CAP structure.
[0053] In a 28th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12", 13th, 14", 15th,
16", 17th, 18th, 19th, 20th, 21st, 22nd and 23rd, 24", 2,,-,,-th,
D
26th and 27th embodiment of the second
aspect, in a 27th embodiment of the third aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12t1, 13th, 14t1, 15th,
16", h , --q,
1 i 18th, 19th, 20th, 21st, 22nd, 23rd, 2 A4 th,
25th and 26th embodiment of the third aspect, in a
28th embodiment of the fourth aspect which is also an embodiment of the first,
second, third,
fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, 12th, 13th,
14th, 15", 16th , 17", 18th ,
19th, 20th, 21st , 22nd, 23rd, 2 A4 th,
25th, 26th and 27th embodiment of the fourth aspect, and in a 27th
embodiment of the fifth aspect which is also an embodiment of the first,
second, third, fourth,
13_,14t.. 15t.., 16_, -,
fifth, sixth, seventh, eighth, ninth, tenth, eleventh 12th, 13th 14th b
16th 17th 18th, 19th, 20th,
21st, 22nd, 23rd, 24th
25th and 26" embodiment of the fifth aspect, the construct comprises one
or more IRES s (internal ribosomal entry sites) sequences. In a preferred
embodiment, the IRES
sequences replaced the Cap structure.
[0054] In a 29" embodiment of the second aspect which is also an embodiment of
the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14", 15th,
16t1, 17th, 116 + nth,
19th, 20th, 21st, 22nd and 23rd, 24th, 25th, 26th , 27th and 28th embodiment
of the
second aspect, in a 28th embodiment of the third aspect which is also an
embodiment of the
first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh, 12th, 13th, 14th,
15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 2 A4 th,
25th, 26th and 27th embodiment of the third
aspect, in a 29" embodiment of the fourth aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th, 16th
, 17th, 18th,
19th, 20th, 21st, 22nd, ,,,srd ,
Li
24th, 25th, 26th, 27th and 28th embodiment of the fourth
aspect, and in a 28th embodiment of the fifth aspect which is also an
embodiment of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh
12th, 13th 14th 15th, 16th,
26
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
17th, id + ,-,th,
1
19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th and 27t1i embodiment of the
fifth aspect, the
construct comprises nucleic acid sequence coding for a signal peptide.
[0055] In a 30th embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th,
16t1, 17th, lid, ,-,th,
19th, 20th, 21st, 22nd and 23rd, 24th, 25th, 26th,27th, 28th and 29th
embodiment of
the second aspect, in a 29th embodiment of the third aspect which is also an
embodiment of the
first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh, 12th, 13th, 14th,
15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th,26th, 27tz
and 28"h embodiment of the
third aspect, in a 30th embodiment of the fourth aspect which is also an
embodiment of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th, 16th
, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th , 27th 28th and
29t1 embodiment of the fourth
aspect, and in a 29"h embodiment of the fifth aspect which is also an
embodiment of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh
12th, 13th 14th 15th, 16th,
1 /
1 -,th ,
18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th 26th, 27th and 28t1 embodiment
of the fifth aspect,
the signal peptide allows secretion of the effector molecule.
[0056] In a 31st embodiment of the second aspect which is also an embodiment
of the first,
second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh,
12th, 13th, 14th, 15th,
16t1, 17th, 18th, 19th, 20th, 21st, 22nd and 23rd, 24th, 25th, 26th ,
27th,28th, 29th and 30th embodiment
of the second aspect, in a 30th embodiment of the third aspect which is also
an embodiment of
the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh, 12th, 13th, 14th,
15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 2, ,-,-
-,th,
/
28th and 29t1 embodiment of
the third aspect, in a 315t embodiment of the fourth aspect which is also an
embodiment of the
first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth,
eleventh, 12th, 13th, 14th,
15th, 16th , 17th 18th , 19th, 20th, 21st , 22nd, L,-,,sird,
24th, 25th, 26th, 27th,28th, 29th and 30th
embodiment of the fourth aspect, and in a 30th embodiment of the fifth aspect
which is also an
embodiment of the first, second, third, fourth, fifth, sixth, seventh, eighth,
ninth, tenth, eleventh
12t11, 13th,14th 15th, 16th, 17th, id , ,-,th,
1
19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th and 29th
embodiment of the fifth aspect, the nucleotide sequence coding for a signal
peptide is selected
from the group comprising a nucleotide sequence coding for a signal peptide of
MCP-1 or a
derivative thereof having a nucleotide identity of at least 85 %, nucleotide
sequence coding for
a signal peptide of IL-6 or a derivative thereof having a nucleotide identity
of at least 85 %õ
a nucleotide sequence coding for a signal peptide of Ang-2 or a derivative
thereof having a
27
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
nucleotide identity of at least 85 %, and a nucleotide sequence coding for a
signal peptide of
Ang-1 or a derivative thereof having a nucleotide identity of at least 85 %.
[0057] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the cell a cellular function of which is restored and/or
the cell in or on
which a therapeutic effect is exercised is an endothelial cell, preferably a
vascular endothelial
cell, more preferably the vascular endothelial cell is a microvascular
endothelial cell.
[0058] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the endothelial cell is a non-dividing endothelial cell, a
non-proliferating
endothelial cell or a resting endothelial cell.
[0059] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the endothelial cell is an endothelial cell stimulated by
an inflammatory
stimulus.
[0060] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the endothelial cell is a senescent endothelial cell.
[0061] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the endothelial cell is impaired by age and/or showing
stress-related
defects.
[0062] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the cellular function is one which can be restored by an
effector molecule
having anti-permeability effect of endothelial cells, an anti-vascular leakage
effect, an anti-
apoptotic effect of endothelial cells or an anti-inflammatory effect of
endothelial cells or an
anti-stress response effect. In an embodiment thereof, the effector molecule
stimulates vessel
survival, inhibits regression, inhibits apoptosis, stimulates migration,
stimulates remodelling,
stimulates angiogenesis, stimulates tube-formation/invasion, stimulates
proliferation, inhibits
leucocyte adhesion, inhibits adhesion molecule expression, inhibits tissue
factor expression,
inhibits NFKappaB activity or promotes monolayer integrity.
28
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0063] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effect is linked to or associated with the Tie-2
signalling pathway,
VEGF-receptor pathway, NOTCH signalling pathway, P13-kinase pathway, eNOS
signalling
pathway, sirtuin-dependent metabolic and energy homeostasis pathway, oxidative
stress
pathway, shear stress response pathway, ET-1 signal transduction pathway, NO-
mediated
signal transduction pathway, and mechanochemical transduction pathway,
preferably the
pathway is selected from the group comprising Ang/Tie-2 signalling pathway,
VEGF/VEGF
receptor pathway and Notch/Notch ligand pathway.
[0064] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is an element of a pathway, wherein
the pathway is
selected from the group comprising the Tie-2 signalling pathway, VEGF-Receptor
pathway,
NOTCH signalling pathway, P13-kinase pathway, eNOS signalling pathway, sirtuin-
dependent
metabolic and energy homeostasis pathway, oxidative stress pathway, shear
stress response
pathway ET-1 signal transduction pathway, NO-mediated signal transduction
pathway, and
mechanochemical transduction pathway.
[0065] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is selected from the group
comprising Ang-1, Ang-
4, COMP-Ang-1, hCOMP-Ang-1, COMP-Ang-1, COMP-ANG-2, Tie-2 receptor, Tie-1
receptor, PI3-kinase, preferably constitutive active P13-kinase, hyperactive
Tie-2 receptor (e.g.
R849W), VE-cadherin, GRB2, GRB7, GRB14, GRB7, IQGAP1, RAC1, RAP1, DOK2,
ABIN1 and ABIN2, KLF2 (Krueppel-like factor 2), a1pha5 betal integrin, CD73,
Akt 1, Akt
2 and Akt 3.
[0066] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the cellular function is vascular leakage and, preferably,
the pathway is
the Tie-2 pathway.
[0067] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is selected from the group
comprising VEGF,
VEGF-A, VEGF-B, PDGF, bFGF, Sirtuin, eNOS, RAS and c-MYC.
29
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0068] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, wherein the effector molecule restores vascular
regeneration or provides
for vascular regeneration, preferably vascular endothelial vascular
regeneration
[0069] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the cell a cellular function of which is restored and/or
the cell in or on
which a therapeutic effect is exercised is a non-endothelial cell.
[0070] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the non-endothelial cell is selected from the group
comprising epithelial
cells, alveolar macrophages, Alveolar type I cells, alveolar type II cells,
alveolar macrophages,
Pneumocytes, lung epithelial cells, hematopoietic cells, bone marrow cells,
bone cells, stem
cells, mesenchymal cells, neural cells, glia cells, neuron cells, Astrocytes,
cells of the peripheral
nervous system, cardiac cells, adipocytes, vascular smooth muscle cells,
cardiomyocytes,
skeletal muscle cells, beta cells, pituitary cells, synovial lining cells,
ovarian cells, testicular
cells, B cells, T cells, reticulocytes, leukocytes, granulocytes, macrophages,
neutrophils,
antigen presenting cells (dendritic cells), fibroblasts, hepatocytes, tumor
cells and combination
thereof.
[0071] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is selected from the group
comprising a tumor death
ligand, a factor involved in hematopoiesis and blood clotting, a stem cell
factor, a growth factors
and a cytokine.
[0072] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the tumor death ligand is selected from the group
comprising IL-12,
members of the TNF gene superfamily of death ligand proteins such as
Apo2L/TRAIL, IL-13,
IL-10, IL-8, IL-2, interferon beta, secreted frizzled-related protein (SFRP)
1, SFRP 2, SFRP 3,
SFRP 4 and SFRP5.
[0073] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, wherein the factor involved in hematopoiesis and blood
clotting is selected
from the group comprising erythropoietin, Factor VII, Factor VIII, Factor IX
and heparan-N-
sulfatase.
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0074] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the stem cell factor is selected from the group comprising
0ct4, Sox2,
Klf4 and c-Myc.
[0075] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the growth factor and cytokine is selected from the group
comprising
adrenomedullin, angiopoietin family, autocrine motility factor, bone
morphogenetic proteins,
ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF),
interleukin-6 (IL-6),
macrophage colony-stimulating factor (m-CSF), granulocyte colony-stimulating
factor (G-
CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), epidermal
growth fac-tor
(EGF), ephrins, erythropoietin (EPO), fibroblast growth factor family (FGF1-
23),
somatotropin, GDNF family of ligands (such as glial cell line-derived
neurotrophic factor
(GDNF), neurturin, persephin, and artemin), growth differentiation factor-9
(GDF9),
hepatocyte growth factor (HGF), hepatoma-derived growth factor (HDGF),
insulin, insulin-like
growth factors -1 and-2 (IGF-1; IGF-2), keratinocyte growth factor (KGF),
migration-
stimulating factor (MSF), macrophage-stimulating protein (MSP), also known as
hepatocyte
growth factor-like protein (HGFLP), myostatin (GDF-8), neuregulins 1-4 (NRG1-
4),
neurotrophins (brain-derived neurotrophic factor (BDNF), nerve growth factor
(NGF),
neurotrophin-3 (NT-3), neurotrophin-4 (NT-4)), placental growth factor (PGF),
platelet-
derived growth factor (PDGF), renalase (RNLS) - anti-apoptotic survival
factor, T-cell growth
factor (TCGF), thrombopoietin (TPO), transforming growth factor alpha (TGF-a),
transforming growth factor beta (TGF-I3), tumor necrosis factor-alpha (TNF-a),
vascular
endothelial growth factor family (VEGF), Wnt Signaling Pathway signaling
glycoproteins
(WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A,
WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16),
granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-
stimulating
factor (GM-CSF), interferon- alfa, interferon-beta, interleukin 2 (IL-2),
Interleukin 11 (IL-11),
Interferon-gamma, IL-1, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-
12, IL-13, IL-14,
IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23,IL-24, IL-25, IL-
26, IL-27, IL-
28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-35 and IL-36.
31
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0076] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the disease is characterized by or caused by vascular
leakage, preferably
leakage of vascular endothelial cells, more preferably leakage of micro
vascular endothelial
cells.
[0077] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, a subject suffering from the disease shows inflammation in
the lung.
[0078] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the disease wherein the disease is selected from the group
comprising
pneumonia, sepsis and trauma.
[0079] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, a subject suffering from the disease shows acute
respiratory distress
syndrome (ARDS).
[0080] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, disease is pneumonia, preferably pneumonia selected from
the group
comprising severe community-acquired pneumonia (sCAP), community acquired
pneumonia
(CAP), hospital-acquired pneumonia (HAP).
[0081] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the disease is characterized by or shows lung damage.
[0082] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, lung damage is immediate lung damage.
[0083] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, immediate lung damage results from inhalation of toxic
gases, toxic lung
edema, lung infection of a virus or bacterium, aspiration of stomach contents,
aspiration of fresh
water, aspiration of salt water, pulmonary contusion, fat embolism, amniotic
fluid embolism
and inhalation of hyperbaric oxygen.
[0084] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, lung damage is indirect lung damage.
32
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0085] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, indirect lung damage results from sepsis, bacteremia,
endotoxinemia,
severe trauma, polytrauma including shock, burns, pancreatitis, malaria
tropica, drugs and
immunosuppression, chronic alcohol abuse, chronic pulmonary diseases, low pH
of serum.
[0086] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the disease or effect is vascular regeneration or
longevity, wherein
preferably the effector molecule is selected from the group comprising VEGF,
VEGF-A,
VEGF-B, PDGF, bFGF, Sirtuin (Sirt 1), PPAR-gamma, AMPK, eNOS, RAS, c-MYC,
FOX03,
PI3 kinase *, Akt, Akt* (* indicates fusion or truncated versions of the
proteins to generate
hyperactive and constitutively active derivatives of the kinases), adenosine
Al receptor,
adenosine A2A receptor, adenosine A2B receptor, telomerase, Yamanaka factors
(namely
0ct4, sox2, k1f4, c-My).
[0087] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is an antiapoptotic factor,
preferably protecting
normal, i.e. non-diseased endothelium, wherein the antiapoptotic factor is
preferably selected
ffrom the group comprising PTEN, survivin, TAP, cIAP2 and XIAP, neuroglobin
(binds
cytochrome c), prosurvival pro-teins Bc1-2, Bcl-xl, Bcl-w, mcl-1 Al, NR-13,
BHRF1, LMW5-
HL, 0RF16, KS-Bc1-2, E lb-19K and P53.
[0088] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is an apoptotic factor, preferably
targeting tumor
endothelium, wherein the apoptotic factor is preferably selected from the
group comprising
PTEN, survivin, TAP, cIAP2 and XIAP, neuroglobin (binds cytochrome c),
prosurvival pro-
teins Bc1-2, Bcl-xl, Bcl-w, mc1-1 Al, NR-13, BHRF1, LMW5-HL, 0RF16, KS-BC1-2,
Elb-
19K, P53.
[0089] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is a tumor death ligand, preferably
the tumor death
ligand is proapoptotic or anti-angiogenic, more preferably the tumor death
ligand is selected
from the group comprising Members of the TNF gene superfamily of death ligand
proteins such
as TNF-alpha, Fas-L, Apo2L/TRAIL, IL-12, IL-13, IL-10, IL-8, IL-2õ secreted
frizzled-related
protein (SFRP) family (SFRP1, 2, 3, 4, 5), ELTD1, TGF-B, TNF-a, IL-6, PTEN,
p53 and other
tumor suppressor genes with proapoptotic function, thrombospondin C, TIMP-1,
TIIVIP-2,
33
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
interferon-alpha, interferon-beta, interferon-gamma, Ang-1 and derivatives
with Tie-2
agonistic function, cytochrome c, BH3-only proteins, pro-apoptotic Bc1-2
proteins Bad, Bid,
Bax, Bak and Bim, Apafl, procaspase-8, -9 -10, caspases 2, 3, 6, 7, 8, 9 and
10.
[0090] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is anti-inflammatory, preferably the
effector
molecule is selected from the group comprising IkappaB and derivative with
mutated
phosphorylation sites, PI3 kinase and Akt kinases and hyperactive forms.
[0091] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is active in blood coagulation
and/or hematopoiesis,
preferably the effector molecule is selected from the group comprising
erythropoietin, factor
VII, factor VIII, factor IX and heparan-N-sulfatase.
[0092] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is a gene editing nuclease such as
Cas9.
[0093] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is coding for a therapeutic antibody
or a decoy.
[0094] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is effective as a tumor vaccine,
preferably the
effector molecule is an antigen eliciting an immune response against a tumor
cell.
[0095] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is a secreted protein
[0096] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is effective as an autocrine factor.
[0097] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the effector molecule is effective as a paracrine factor.
[0098] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the recombinant nucleic acid construct consists of
ribonucleotides.
34
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[0099] In an embodiment of the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, the recombinant nucleic acid construct consists of
deoxyribonucleotides.
[00100] In an embodiment of the first, second, third, fourth and fifth
aspect, including
any embodiment thereof, the recombinant nucleic acid construct consists of
ribonucleotides and
deoxyribonucleotides .
[00101] More specifically, the problem underlying the present invention is
solved in a
sixth aspect which is also a first embodiment of the sixth aspect, by a vector
comprising a
recombinant nucleic acid construct of the first aspect, including any
embodiment thereof, and/or
a recombinant nucleic acid construct as described in connection with each and
any aspect,
including any embodiment thereof, preferably of the second, third, fourth and
fifth aspect.
[00102] In a second embodiment of the sixth aspect which is also an
embodiment of the
first embodiment of the sixth aspect, the vector is an expression vector.
[00103] In a third embodiment of the sixth aspect which is also an
embodiment of the
second embodiment of the sixth aspect, the vector allows expression of the
recombinant nucleic
acid construct in a cell, preferably an endothelial cell, more preferably the
vector is a plasmid
or a virus.
[00104] More specifically, the problem underlying the present invention is
solved in a
seventh aspect which is also a first embodiment of the seventh aspect, by a
cell comprising a
recombinant nucleic acid construct according to the first, second, third,
fourth and fifth aspect,
including any embodiment thereof, and/or a vector according to the seventh
aspect, including
any embodiment thereof.
[00105] In a second embodiment of the seventh aspect which is also an
embodiment of
the first embodiment of the seventh aspect, the cell is an endothelial cell or
a mesenchymal stem
cell.
[00106] In a third embodiment of the seventh aspect which is also an
embodiment of the
first and second embodiment of the seventh aspect, the cell is a recombinant
cell.
[00107] In a fourth embodiment of the seventh aspect which is also an
embodiment of
the first, second and third embodiment of the seventh aspect, the cell is an
isolated cell.
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00108] More specifically, the problem underlying the present invention is
solved in an
eighth aspect which is also a first embodiment of the eighth aspect, by a
delivery vehicle
comprising a recombinant nucleic acid construct according to the first,
second, third, fourth and
fifth aspect, including any embodiment thereof, wherein the delivery vehicle
is a cationic lipid
delivery particle.
[00109] In a second embodiment of the eighth aspect which is also an
embodiment of the
first embodiment of the eighth aspect, the particle is a nanoparticle.
[00110] In a third embodiment of the eighth aspect which is also an
embodiment of the
first and second embodiment of the eighth aspect, the average size of the
nanoparticle is from
about 30nm to about 200 nm, preferably from about 30 nm to about 140 nm and
more preferably
from about 30 nm to about 60 nm.
[00111] More specifically, the problem underlying the present invention is
solved in a
ninth aspect which is also a first embodiment of the ninth aspect, by a
composition comprising
a recombinant nucleic acid construct according to the first, second, third,
fourth and fifth aspect,
including any embodiment thereof, a vector according to the sixth aspect,
including any
embodiment thereof, a cell according to the seventh aspect, including any
embodiment thereof,
and/or a delivery vehicle according to the eight aspect, including any
embodiment thereof. In a
preferred embodiment, the composition is a pharmaceutical composition
comprising a
pharmaceutically acceptable excipient.
[00112] More specifically, the problem underlying the present invention is
also solved in
a tenth aspect by the use in the manufacture of a medicament of a recombinant
nucleic acid
construct according to the first, second, third, fourth and fifth aspect,
including any embodiment
thereof, a vector according to the sixth aspect, including any embodiment
thereof, a cell
according to the seventh aspect, including any embodiment thereof, a cell
according to the
seventh aspect, including any embodiment thereof, and/or a delivery vehicle
according to the
eight aspect, including any embodiment thereof. In an embodiment thereof, the
medicament is
for the treatment of a disease, preferably a disease described herein in
connection with the
second, third, fourth and fifth aspect, including any embodiment thereof.
[00113] More specifically, the problem underlying the present invention is
also solved in
an eleventh aspect by a method for treating a subject, preferably a human
subject, wherein the
method comprises administering to the subject a therapeutically effective
amount of a
36
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
recombinant nucleic acid construct according to the first, second, third,
fourth and fifth aspect,
including any embodiment thereof, a vector according to the sixth aspect,
including any
embodiment thereof, a cell according to the seventh aspect, including any
embodiment thereof,
a delivery vehicle according to the eight aspect, including any embodiment
thereof and/or a
composition according to the ninth aspect, including any embodiment thereof.
In an
embodiment thereof, the method is for the treatment of a disease, preferably a
disease described
herein in connection with the second, third, fourth and fifth aspect,
including any embodiment
thereof.
[00114] More specifically, the problem underlying the present invention is
also solved in
an twelfth aspect by a method for vaccinating a subject, preferably a human
subject, wherein
the method comprises administering to the subject an amount effective to
elicit in a or the
subject an immune response, preferably a desired immune response, of a
recombinant nucleic
acid construct according to the first, second, third, fourth and fifth aspect,
including any
embodiment thereof, a vector according to the sixth aspect, including any
embodiment thereof,
a cell according to the seventh aspect, including any embodiment thereof, a
delivery vehicle
according to the eight aspect, including any embodiment thereof and/or a
composition
according to the ninth aspect, including any embodiment thereof. In an
embodiment thereof,
the method is for the treatment of a disease, preferably a disease described
herein in connection
with the second, third, fourth and fifth aspect, including any embodiment
thereof. In a preferred
embodiment, the effector molecule is one which is capable of or suitable for
eliciting such
immune response.
[00115] In an embodiment and as preferably used herein, a heterologous
construct or
recombinant construct is a construct which as such is not existing in a wild
type biological
system such as a virus, a cell, a tissue, an organ or an organism. More
preferably, a heterologous
construct or a recombinant construct is one, where at least one element
contained in the
construct is not combined with a coding region for the effector, wherein said
element is selected
from the group consisting of a 5' non-translated region, a 3' non-translated
region, a cap
structure, a signal sequence and a poly-A tail. Preferably, the 5' non-
translated region is a 5'
UTR and the 3' non-translated region is a 3' UTR.
[00116] In an embodiment and as preferably used herein, a therapeutic
method or a
method for the treatment and/or prevention of a disease is a therapy.
37
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00117] In an embodiment of each and any aspect of the present invention,
the coding
region coding for an effector molecule is expressed by an endothelial cell. In
preferred
embodiment thereof, the endothelial cell expressing the effector molecule is
an endothelial cell
the function of which is impaired. In an alternative preferred embodiment, the
endothelial cell
expressing the effector molecule is an endothelial cell the function of which
is not impaired; in
such case, the effector molecule is exported or secreted by the effector
molecule producing
endothelial cell and exerts its effect on any other cell, typically any other
endothelial cell,
whereby such other cell is one the function of which is impaired. In a
preferred embodiment,
an impaired function of a cell is function of such cell which is to be
restored in according with
the present invention in its various aspect.
[00118] As preferably used herein, a derivative of a sequence which
displays the same
function as the parent sequence; preferably the parent sequence is a or the
wild type sequence.
In a preferred embodiment, the sequence of the derivative and of the parent
case have an identity
of at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%,
63%,
64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%,
79%,
80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%,
96%, 97%, 98%, 99% or 100%. It is within the present invention that the
derivative is a
truncated version of the parent sequence. Such truncation may exist at the 5'
end, the 3' end or
both the 5' end and the 3' end. If reference is made to a parent sequence in
terms of identity,
such identity preferable refers to a stretch of subsequent nucleotides shared
by both the
derivative and the parent sequence with the sequence of the parent sequence
serving as the
reference sequence.
[00119] In an embodiment and as preferably used herein, a coding region
coding for an
effector molecule comprises or consists of a nucleic acid sequence coding to
said effector
molecule.
[00120] In an embodiment and as preferably used herein, a 5' non-translated
region is a
5' non-translated sequence.
[00121] In an embodiment and as preferably used herein, a 3' non-translated
region is a
5' non-translated sequence.
38
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00122] In an embodiment and as preferably used herein, the indication of
any source of
any one of the elements contained in the recombinant nucleic acid construct of
the invention is
to be understood as a substitute of or an alternative description of a
nucleotide sequence. Such
nucleotide sequence is preferably the one of the respective wild type
sequence, more preferably
the one of the respective human wild type sequence. It will be appreciated by
a person skilled
in the art that other species than man may provide such wild type sequence; in
an embodiment
of the present invention such wild type sequence for such other species than
man may be used
in the practicing of the present invention. It will also be appreciated by a
person skilled in the
art that such wild type sequence may be taken from publicly available data
bases such as
GenBank. The wild type sequence may be subject to changes over time, typically
to correct
sequencing errors. In an embodiment of the invention, the sequence is the one
described in said
publicly available data bases such as GenBank at the date of filing of the
instant application.
To the extent various respective wild type sequences exist, each and any such
wild type
sequence shall be encompassed by the present invention. In another embodiment,
where there
is more than one wild type sequences and the more than one wild type sequence
is provided by
different groups of people such as different geographically defined groups of
people and/or
different genetically defined groups of people, the wild type sequence
prevailing in the most
comprehensive group of said different groups of people may be regarded as the
wild type
sequence.
[00123] In an embodiment of the present invention and as preferably used
herein, if
reference is made to a derivative of a 5' UTR of a gene indicating that the
derivative has a
nucleotide identity of at least 85 %, identity is identity referring or
relative to the 5' UTR of the
gene.
[00124] In an embodiment of the present invention and as preferably used
herein, if
reference is made to a derivative of a 3' UTR of a gene indicating that the
derivative has a
nucleotide identity of at least 85 %, identity is identity referring or
relative to the 3' UTR of the
gene.
[00125] In an embodiment and as preferably used herein, a signal peptide is
a peptide
which mediates directly or indirectly the transfer or secretion of a
polypeptide or a protein fused
or attached to the signal peptide into the extracellular space, whereupon,
preferably, the signal
sequence is removed from the polypeptide and protein, respectively.
39
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00126] In an embodiment of the present invention, the recombinant nucleic
acid
construct is a recombinant nucleic acid construct disclosed in the Figs, more
specifically a
recombinant nucleic acid construct disclosed in Fig. 40 (PAN29), Fig 90
(PAN58), Fig 86
(PAN54), Fig 67 (PAN50), Fig 45 (PAN34), Fig 44 (PAN33), Fig 39 (PAN28), Fig
37
(PAN12), Fig 88 (PAN56).
[00127] In an embodiment of the present invention and as preferably used
herein, a decoy
is a mRNA encoded protein which binds a ligand and neutralizes the signaling
activity.
[00128] In an embodiment and as preferably used herein, a poly-A tail is a
nucleotide
sequence comprising or consisting of a plurality of A's covalently attached to
each other,
whereby such covalent linkage is preferably a phosphodiester linkage. In an
embodiment
thereof, the poly-A tail comprises about 20 to about 240 As (i.e.
adenosinphosphates)
nucleotides, preferably about 60 to 120 As, more preferable about 100 to 140
As and most
preferably about 120 As.
[00129] The poly A tail is thought to stabilize natural messengers and
synthetic sense
RNA. Therefore, in one embodiment a long poly A tail can be added to an mRNA
molecule
thus rendering the RNA more stable. Poly A tails can be added using a variety
of art-recognized
techniques. For example, long poly A tails can be added to synthetic or in
vitro transcribed
RNA using poly A polymerase (Yokoe, et al. Nature Biotechnology. 1996; 14:
1252-1256). A
transcription vector can also encode long poly A tails. In addition, poly A
tails can be added by
transcription directly from PCR products. Poly A may also be ligated to the 3'
end of a sense
RNA with RNA ligase (see, e.g., Molecular Cloning A Laboratory Manual, 2nd
Ed., ed. by
Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1991
edition)). In one
embodiment, the length of the poly A tail is at least about 90, 200, 300, 400
at least 500
nucleotides. In one embodiment, the length of the poly A tail is adjusted to
control the stability
of a modified sense mRNA molecule of the invention and, thus, the
transcription of protein.
For example, since the length of the poly A tail can influence the half-life
of a sense mRNA
molecule, the length of the poly A tail can be adjusted to modify the level of
resistance of the
mRNA to nucleases and thereby control the time course of protein expression in
a cell. In one
embodiment, the stabilized nucleic acid molecules are sufficiently resistant
to in vivo
degradation (e.g., by nucleases), such that they may be delivered to the
target cell without a
transfer vehicle. In yet another embodiment the nucleic acid molecule can be
purified by means
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
of HPLC in order to remove double-stranded RNA contaminants and thus to reduce
innate
immune system activation (see e.g. Kariko et al., Nucleic Acids Res. 2011 Nov;
39(21):e142).
[00130] In an embodiment and as preferably used herein, the CAP structure
is a
nucleotide sequence forming a CAP structure which is known to a person skilled
in the art. In
eukaryotic cells the CAP-structure consists of a m7G(5')ppp(5')G 5' -5' -
triphosphate linkage
structure. The first two ribose sugars at the 5' -end of the mRNA can be
methylated in the
2' -position which is known as CAP-1 (in case the first of the two ribose
sugars is methylated)
and CAP-2 structure (in case the second of the two ribose sugars is
methylated). The CAP-
structure can be incorporated during the mRNA transcription or post-
transcriptionally by using
capping and 2' -0-Methyltransferase enzymes and S-adenosylmethionine (SAM) as
a methyl
donor. In addition, a phosphatase treatment can be used in order to remove
immune stimulatory
5' -phosphates.
[00131] In a preferred embodiment of the recombinant nucleic acid construct
according
to each and any aspect, including any embodiment thereof, the recombinant
nucleic acid
construct is an mRNA.
[00132] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for MCP-1 comprises a nucleotide
sequence
of SEQ ID NO: 20.
[00133] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for MCP-1 comprises a nucleotide
sequence
of SEQ ID NO: 23.
[00134] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for RPL12s.c. comprises a
nucleotide sequence
of SEQ ID NO: 24.
[00135] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for RPL12s.c. comprises a
nucleotide sequence
of SEQ ID NO: 25.
41
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00136] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for Ang-2 comprises a nucleotide
sequence of
SEQ ID NO: 26.
[00137] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for Ang-2 comprises a nucleotide
sequence of
SEQ ID NO: 29.
[00138] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for HSP70 comprises a nucleotide
sequence
of SEQ ID NO: 38 or 40.
[00139] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for HSP70 comprises a nucleotide
sequence
of SEQ ID NO: 39 or 43.
[00140] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for H3.3. comprises a nucleotide
sequence of
SEQ ID NO: 44.
[00141] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for H3.3. comprises a nucleotide
sequence of
SEQ ID NO: 45.
[00142] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for Galectin-9 (LHALS9)
comprises a
nucleotide sequence of SEQ ID NO: 46.
[00143] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for Galectin-9 (LHALS9)
comprises a
nucleotide sequence of SEQ ID NO: 47.
[00144] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for IL-6 comprises a nucleotide
sequence of
SEQ ID NO: 30.
42
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00145] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for IL-6 comprises a nucleotide
sequence of
SEQ ID NO: 33.
[00146] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for vWF comprises a nucleotide
sequence of
SEQ ID NO: 34.
[00147] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for vWF comprises a nucleotide
sequence of
SEQ ID NO: 37.
[00148] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for Ang-1 comprises a nucleotide
sequence of
SEQ ID NO: 83.
[00149] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for Ang-1 comprises a nucleotide
sequence of
SEQ ID NO: 88.
[00150] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of a gene coding for Ang-4 comprises a nucleotide
sequence of
SEQ ID NO: 89.
[00151] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of a gene coding for Ang-4 comprises a nucleotide
sequence of
SEQ ID NO: 94.
[00152] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 5' UTR of construct PAN57 comprises a nucleotide
sequence of SEQ
ID NO: 120.
[00153] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, a 3' UTR of construct PAN57 comprises a nucleotide
sequence of SEQ
ID NO: 121.
43
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00154] In an embodiment of each and any aspect of the present invention,
including any
embodiment thereof, the various combinations of a 5' UTR and a 3' UTR as
realized in each
and any of the specific constructs disclosed herein is a combination of 5' UTR
and a 3' UTR
which may be realized in recombinant nucleic acid construct irrespective of
any other
constituent and in particular irrespective of any coding region coding for an
effector molecule
contained in a recombinant nucleic acid construct of the invention.
[00155] In an embodiment of each and any aspect of the present in
invention, including
any embodiment thereof, and as preferably used herein, an endogenous gene is a
gene contained
in any cell described herein. In accordance therewith, a recombinant nucleic
acid construct
where the 5' UTR and the 3' UTR are from different endogenous genes, comprises
a 5' UTR
from a first gene of a cell and a 3' UTR from a second gene of a cell, for
example the 5' UTR
is from a gene encoding MCP-1 or Ang-2, and the 3' UTR is from a gene coding
for vWF. Said
cell may be the same cell or a different cell and/or said cell may be the same
kind of cell or a
different kind of cell. Preferably, the cell is of human origin.
[00156] In a preferred embodiment of the recombinant nucleic acid construct
according
to each and any aspect, including any embodiment thereof, the recombinant
nucleic acid
construct is a recombinant nucleic acid molecule.
[00157] It is within the present invention defined by each and any aspect,
including any
embodiment thereof, that the nucleotides forming the recombinant nucleic acid
molecule may
be modified. Suitable modifications include alterations in one or more
nucleotides of a codon
such that the codon encodes the same amino acid but is more stable than the
codon found in the
wild-type version of the nucleic acid. For example, an inverse relationship
between the stability
of RNA and a higher number cytidines (C's) and/or uridines (U's) residues has
been
demonstrated, and RNA devoid of C and U residues have been found to be stable
to most
RNases (Heidenreich, et al. J Biol Chem 269, 2131-8 (1994)). In some
embodiments, the
number of C and/or U residues in an mRNA sequence is reduced. In another
embodiment, the
number of C and/or U residues is reduced by substitution of one codon encoding
a particular
amino acid for another codon encoding the same or a related amino acid.
Contemplated
modifications to the mRNA nucleic acids of the present invention also include
the incorporation
of pseudouridine, Nl-methyl-pseudouridine, 5-methoxyuridine and 5' -
Methylcytidine. The
incorporation of such modified nucleotides into the recombinant nucleic acid
construct,
preferably the mRNA of the present invention may enhance stability and
translational capacity,
44
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
as well as diminishing immunogenicity in vivo. (See, e.g., Kariko, K., et al.,
Molecular Therapy
16 (11): 1833-1840 (2008)). Substitutions and modifications to the recombinant
nucleic acid
construct of the present invention, particularly at the level of the
individual nucleotide of the
recombinant nucleic acid construct, may be performed by methods readily known
to one of
ordinary skill in the art.
[00158] The constraints on reducing the number of C and U residues in a
sequence will likely
be greater within the coding region of an mRNA, compared to an untranslated
region, (i.e., it
will likely not be possible to eliminate all of the C and U residues present
in the message while
still retaining the ability of the message to encode the desired amino acid
sequence). The
degeneracy of the genetic code, however presents an opportunity to allow the
number of C
and/or U residues that are present in the sequence to be reduced, while
maintaining the same
coding capacity (i.e., depending on which amino acid is encoded by a codon,
several different
possibilities for modification of RNA sequences may be possible). For example,
the codons for
Gly can be altered to GGA or GGG instead of GGU or GGC.
[00159] The term modification also includes, for example, the incorporation of
non-nucleotide
linkages or modified nucleotides into the nucleic acid sequences of the
present invention (e.g.,
modifications to one or both the 3' and 5' ends of an mRNA molecule encoding a
functional
protein or enzyme). Such modifications include the addition of bases to a
nucleic acid sequence
(e.g., the inclusion of a poly A tail or a longer poly A tail), the alteration
of the 3' UTR or the
5' UTR, complexing the nucleic acid with an agent (e.g., a protein or a
complementary nucleic
acid molecule), and inclusion of elements which change the structure of a
nucleic acid molecule
(e.g., which form secondary structures).
[00160] The delivery vehicle according to the eighth aspect is preferably
based on a
composition of one or more suitable lipids (e.g. liposomes) which in
combination with the
recombinant nucleic acid construct according to the present invention result
in overall cationic-
lipid-nucleic acid particles (cLNPs). Such cLNPs can be used for functionally
transferring a
nucleic acid, particularly an mRNA, into endothelial cells of the mammalian
vasculature.
[00161] Lipid-nucleic acid nanoparticles (LNPs) formed by complexation of
nucleic acids such
as the recombinant nucleic acid construct of the present invention with
cationic lipids in
combination with other lipidic components, such as zwitterionic phospholipids,
cholesterol and
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
PEGylated lipids, have already been used to block degradation of RNAs in
plasma and to
facilitate the functional cellular uptake of the RNAs.
[00162] However, in a therapeutic context, particularly in view of parenteral
therapeutic
applications, the overall charge of the lipid-nucleic acid nanoparticles,
characterized by the
Zeta-potential, is essential in directing the organ distribution of the
nanoparticles. Someone
skilled in the art will appreciate that overall neutrally charged LNPs are
almost exclusively
taken up by organs of the reticuloendothelial system, particularly by the
liver and spleen. On
the other hand, it is also known to those skilled in the art, that overall
positively charged lipid
nanoparticles are particularly useful to functionally deliver a pharmaceutical
payload into cells
of the mammalian vasculature.
[00163] Those skilled in the art will also appreciate that free nucleic acids,
particularly
mRNAs, are immune stimulatory if applied intravenously.
[00164] Thus, in view of parenteral therapeutic applications a thorough and
stable
complexation of the nucleic acid inside the lipidic nanoparticle will be
essential in order to
prevent undesired immunogenic side reactions. Furthermore, it is also known to
those skilled
in the art that the size of the lipid-nucleic acid nanoparticle is crucial in
suppressing the
reticuloendothelial clearance of the particles.
[00165] It has recently been described that highly potent limit sized siRNA
LNPs (-30 nm
mean particle size) can be prepared using a microfluidic mixing process based
on a staggered
herringbone micromixer (SHM) device (Belliveau et al.; Molecular Therapy-
Nucleic Acids
(2012) 1(8)).
[00166] Due to the millisecond mixing of the lipids and the nucleic acid such
as the
recombinant nucleic acid construct of the invention on a nanoliter scale, the
resulting particles
are characterized by a very tight packaging of the nucleic acid inside a
dense, solid particle
core. On the contrary, those skilled in the art will appreciate that
macrofluidic mixing processes
using T-type connectors, generally result in larger nanoparticles with a more
heterogeneous,
multilamellar morphology.
[00167] In an embodiment, the present invention provides novel positively
charged lipid-
nucleic acid nanoparticles comprising a nucleic acid such as recombinant
nucleic acid construct
of the invention for the functional delivery of said recombinant nucleic acid
construct of the
46
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
invention, particularly mRNA, into cells of the mammalian vasculature,
particularly into
endothelial cells of the lung vasculature.
[00168] In an embodiment of the various aspects of the present invention,
including any
embodiment thereof, a cationic lipid selected from the group comprising 13-(L-
Arginy1)-L-2,3-
diamino propionic acid-N-palmityl-N-oleyl-amide, L-Arginy1-13-alanine-N-
palmityl-N-oleyl-
amide, DOTAP (N- [1- (2,3-Dioleoyloxy)propyl] -N,N,N-trimethylammonium methyl-
chloride), DOTMA (1,2-di-O-octadeceny1-3-trimethylammonium propane (chloride
salt)) or
DC-cholesterol is combined with neutral lipids and further shielding lipid
components bearing
a polyethylene glycol (PEG) modification. The neutral lipid can be either a
zwitterionic
phospholipid selected from a group comprising Diphytanoyl-PE (1,2-Diphytanoyl-
sn-glycero-
3-phosphoethanolamine), DOPE (1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine),
DLPE
(1,2-Lauroyl-sn-glycero-3-phosphoethanolamine), DMPE, POPE, DSPE or an
uncharged
sterol lipid selected from a group comprising cholesterol and stigmasterol.
The PEGylated lipid
component is selected from a group comprising methoxyPEG-DSPE, methoxyPEG-DLG,
methoxyPEG-DMG, methoxyPEG-DPG, methoxyPEG-DSG, methoxyPEG-c-DMA,
methoxyPEG-C8-Ceramide, methoxyPEG-C16-Ceramide. In a particular embodiment
the
chain length of the PEG-chain corresponds to a molecular weight in the range
of 750 Da to
5000 Da, preferably in a range of 1500 Da to 3000 Da.
[00169] In another embodiment of the present invention, the molar ratio of the
lipids in the
lipid mixture is in a range of 20 ¨ 80 mol% cationic lipid, 10 ¨ 70 mol%
neutral lipid and 1 ¨
mol% PEGylated lipid, preferably in a range of 35-65 mol% cationic lipid, 35-
65 mol%
neutral lipid and 1-5 mol% PEGylated lipid (with the overall lipid content
being set as 100 %).
[00170] In a preferred embodiment, the cationic lipid is 13-(L-Arginy1)-L-2,3-
diamino
propionic acid-N-palmityl-N-oleyl-amide or L-Arginy1-13-alanine-N-palmityl-N-
oleyl-amide,
the neutral lipid is the phospholipid Diphytanoyl-PE and the PEGylated lipid
is
methoxyPEG2000-DSPE. The molar ratio is 50 mol% cationic lipid, 49 mol%
Diphytanoyl-PE
and 1 mol% mPEG2000-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (sodium salt)).
47
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00171] In yet another embodiment, the mixture of above mentioned lipids is
dissolved in a
water miscible solvent selected from a group comprising ethanol, acetone, 1-
butanol, 2-butanol,
tert. -butanol, 3-methyl- 1-butanol, 2-methyl-1-propanol,
1 -propanol, 2-propanol,
dimethylsulfoxide, preferably from a group comprising ethanol, tert.-butanol
and 1-butanol.
[00172] The dissolved lipid mixture is subsequently rapidly mixed with a
dissolution of a
nucleic acid such as the recombinant nucleic acid construct of the invention
in an aqueous
solvent, resulting in the formation of lipid-nucleic acid nanoparticles
(LNPs). In a preferred
embodiment of the present invention, the mixing is performed using a
microfluidic mixing
device, particularly using a staggered herringbone-type mixing chamber, e.g.
NanoAssemblrTM
(Precision NanoSystems Inc.; Vancouver, Canada) device.
[00173] In yet another embodiment, the mass ratio of total lipids to nucleic
acid nucleic acid
such as the recombinant nucleic acid construct of the invention is in a range
of 5 to 60,
preferably in a range of 15 to 40 and the volumetric mixing ratio of aqueous
nucleic acid
solution to organic total lipid solution is in the range of 1:1 to 6:1,
preferably in the range of
2:1 to 4:1. The mixing flow-rate of the solutions is in the range of 5 ml/min
to 25 ml/min,
preferably in a range of 10 ml/min to 20 ml/min.
[00174] In a certain embodiment of the invention the organic solvent of the
resulting mixture
is removed after the mixing step by dialysis or by tangential flow filtration
using ultrafiltration
membranes, whereby the ultrafiltration membranes can be either hollow fiber
membranes or
flat-screen membranes. The pore size of the ultrafiltration membrane
corresponds to a
molecular weight cutoff in the range of 1500 Da to 500.000 Da, preferably in a
range of 1500
Da to 100.000 Da and even more preferably in a range of 1500 Da to 30.000 Da.
Within the
tangential flow filtration step it is also possible to concentrate the LNPs to
a desired
concentration.
[00175] The mean particle size of the resulting LNPs can be measured using
dynamic light
scattering (DLS) technologies and is preferably in the range of 15 nm to 400
nm, more
preferably in a range of 25 nm to 200 nm and even more preferable the
particles have a size in
the range of 25 nm to 100 nm. The overall particle charge of the LNPs is
positive and the Zeta-
potential of the particles is preferably in a range between +5 mV to +60 mV,
more preferably
in a range of +25 mV to +60mV.
48
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00176] In certain embodiments, the delivery vehicle of the invention is a
liposomal transfer
vehicle, e.g. a lipid nanoparticle or a lipidoid nanoparticle. In one
embodiment, the transfer
vehicle may be selected and/or prepared to optimize delivery of the
recombinant nucleic acid
construct of the invention to a target cell. For example, if the target cell
is an endothelial cell,
the properties of the transfer vehicle (e.g., size, charge and/or pH) may be
optimized to
effectively deliver such transfer vehicle to the target cell, reduce immune
clearance and/or
promote retention in that target cell. Alternatively, if the target cell is in
the central nervous
system (e.g., mRNA such as the recombinant nucleic acid construct of the
invention
administered for the treatment of neurodegenerative diseases may specifically
target brain or
spinal tissue), selection and preparation of the transfer vehicle must
consider penetration of,
and retention within, the blood brain barrier and/or the use of alternate
means of directly
delivering such transfer vehicle to such target cell. In one embodiment, the
compositions of the
present invention may be combined with agents that facilitate the transfer of
exogenous mRNA
(e.g., agents which disrupt or improve the permeability of the blood brain
barrier and thereby
enhance the transfer of exogenous mRNA to the target cells).
[00177] Liposomes (e.g., liposomal lipid nanoparticles) are known to be
particularly suitable
for their use as transfer vehicles of diagnostic or therapeutic compounds in
vivo (Lasic, Trends
Biotechnol, 16: 307-321, 1998; Drummond et al, Pharmacol. Rev., 51: 691-743,
1999) and are
usually characterized as microscopic vesicles having an interior aqua space
sequestered from
an outer medium by a membrane of one or more bilayers. Bilayer membranes of
liposomes are
typically formed by amphiphilic molecules, such as lipids of synthetic or
natural origin that
comprise spatially separated hydrophilic and hydrophobic domains (Lasic,
Trends Biotechnol,
16: 307- 321, 1998). Bilayer membranes of the liposomes can also be formed by
amphiphilic
polymers and surfactants (e.g., polymerosomes, niosomes, etc.). Such liposomes
may also be
used as the lipid moiety in the delivery vehicle of the present invention
comprising a
recombinant nucleic acid construct of the present invention.
[00178] It is to be acknowledged that any feature related to the recombinant
nucleic acid
construct as disclosed in connection with a particular aspect of the present
invention is equally
an embodiment of the recombinant nucleic acid construct of each and any other
aspect of the
present invention, including any embodiment thereof. More specifically, any
embodiment of
the recombinant nucleic acid construct disclosed in connection with the first
aspect is also an
embodiment of the recombinant nucleic acid construct of the second, third and
fourth aspect;
49
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
similarly, any embodiment of the recombinant nucleic acid construct disclosed
in connection
with the second, third and fourth aspect is also an embodiment of the
recombinant nucleic acid
construct of the first aspect.
[00179] It is generally acknowledged in the art that the UTRs flanking a
coding region do not
interfere with the coding region and, more specifically, that the UTRs may, in
principle, be
exchanged without interfering with the expression of the coding region (see,
e.g. WO
2017/100551 Al; Trepotec et al.; Tissue Engineering Part A, Vol 0 Nr ja (Apr.
2018)
(http s ://doi. org/10.1089/ten.TEA.2017 .0485)
[00180] The present invention is further illustrated by the following Figs.
and Examples form
which further features, embodiments and advantages of the present invention
may be taken.
[00181] Fig. 1 is a schematic representation of conventional mRNA molecule
structure.
[00182] Fig. 2 is a schematic representation of selected examples for mRNA
constructs with
the coding sequence with an open reading frame being the one of Nano-
luciferase, namely
PAN02, PAN05, PAN07, PAN08, PAN09, PAN10, PAN11, PAN12, 13, PAN28, PAN29,
PAN30, PAN31, PAN32, PAN33, PAN34, PAN35, PAN36, PAN37, PAN38, PAN39,
PAN40, PAN41, PAN42, PAN43, PAN44, PAN45, PAN46, PAN47, PAN48 and PAN49.
[00183] Fig. 3 is a restriction map of plasmid pcDNA3.1(-) containing
construct PAN11.
[00184] Fig. 4 is a restriction digest map of plasmid pdDNA3.1(-) of Fig. 3.
[00185] Fig. 5 is an 1% agarose gel stained with EtBr showing the non-
linearized (uncut,
supercoiled, right lanes) and linearization product (left lanes) of pcDNA3.1(-
) plasmids
containing constructs PAN28 ("28"), PAN13 ("13"), PAN12 ("12"), PAN11 ("11"),
PAN10
("10"), PANO9 ("09"), PANO8 ("08"), PANO7 ("07") and PANO5 ("05") upon BamHI
restriction.
[00186] Fig. 6 shows 1% agarose gels stained with EtBr showing PCR products of
Poly-A
tailing PCRs for the addition of 120 nt of Poly-A tail.
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00187] Fig. 7A shows the 5' primers used for the 5' UTRs of the indicated
gene; the first
column indicates in connection with which construct such primer is to be used,
the second
column indicates the origin of the 5' UTR, and the third column indicates the
position where
the primer hybridizes to the nucleotide sequence.
[00188] Fig. 7B shows the 3' primers used for the 3' UTRs of the indicated
gene; the first
column indicates in connection with which construct such primer is to be used,
the second
column indicates the origin of the 3' UTR, and the third column indicates the
position where
the primer hybridizes to the nucleotide sequence.
[00189] Fig. 8 is an image of a non-denaturing agarose gel after EtBr staining
showing the in
vitro mRNA transcripts of various construct.
[00190] Fig. 9 are photographs of fluorescence microscopy 24 h post
transfection of HeLa cells
transfected with 0.5 iLtg (left) and 0.1 iLtg (right) of a commercially,
enhanced mRNA version of
the producing green fluorescent protein (TriLINK Biotechnology).
[00191] Fig. 10 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HPMEC where luciferase is used as the effector molecule after 2 hours (left
column), 6 hours
(middle column) and 24 hours (right column) post transfection.
[00192] Fig. 11 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in whole cell lysates of HPMEC, by the indicated
recombinant nucleic
acid constructs in HPMEC, where luciferase is used as the effector molecule
after, 6 hours (left
column) and 24 hours (right column) post transfection.
[00193] Fig. 12 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HUVEC where luciferase is used as the effector molecule after 2 hours (left
column), 6 hours
(middle column) and 24 hours (right column) post transfection.
51
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00194] Fig. 13 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units)] of luciferase in whole cell lysates of HUVEC, by the indicated
recombinant nucleic
acid constructs after lysis of HUVEC, where luciferase is used as the effector
molecule after 2
hours (left column), 6 hours (middle column) and 24 hours (right column) post
transfection.
[00195] Fig. 14 is a bar diagram showing expression of luciferase, indicated
as RLU [(relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HeLa cells where luciferase is used as the effector molecule after 2 hours
(left column), 6 hours
(middle column) and 24 hours (right column) post transfection.
[00196] Fig. 15A shows the 5' UTR nucleotide sequence of the mRNA of human MCP-
1 which
is also referred to as homo sapiens C-C motif chemokine ligand 2 (CCL2)
(GenBank entry
NM_002982.3).
[00197] Fig. 15B shows both the nucleotide sequence and the amino acid
sequence of the signal
peptide sequence of human MCP-1.
[00198] Fig. 15C shows the 3' UTR nucleotide sequence of the mRNA of human MCP-
1.
[00199] Fig. 16A shows the 5' UTR nucleotide sequence of the mRNA of the 50S
ribosomal
protein L12, chloroplastic (LOC110782793), of Spinacia oleracea which is also
referred to as
RPL12s.c. (GenBank entry XM_021987044.1).
[00200] Fig. 16B shows the 3' UTR from the mRNA of the 50S ribosomal protein
L12,
chloroplastic (LOC110782793), of Spinacia oleracea.
[00201] Fig. 17A shows the 5' UTR nucleotide sequence of the mRNA of human
angiopoietin
2 which is also referred to as ANGPT2 or Ang-2, transcript variant 1 (GenBank
entry
NM_001147.2).
[00202] Fig. 17B shows both the nucleotide sequence and the amino acid
sequence of the signal
sequence of the mRNA of human Ang-2.
[00203] Fig. 17C shows the 3' UTR nucleotide sequence of the mRNA of human Ang-
2.
52
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00204] Fig. 18A shows the 5' UTR nucleotide sequence of the mRNA of human
interleukin
6 (IL-6), transcript variant 1 (GenBank entry NM_000600.4).
[00205] Fig. 18B shows both the nucleotide sequence and the amino acid
sequence of the signal
sequence of the mRNA of human IL-6.
[00206] Fig. 18C shows the 3' UTR nucleotide sequence of the mRNA of human IL-
6.
[00207] Fig. 19A shows the 5' UTR nucleotide sequence of the mRNA of human von
Willebrand factor (vWF) (GenBank entry NM_000552.4).
[00208] Fig. 19B shows both the nucleotide sequence and the amino acid
sequence of the signal
sequence of the mRNA of von Willebrand factor (vWF).
[00209] Fig. 19C shows the 3' UTR nucleotide sequence of the mRNA of von
Willebrand
factor (vWF).
[00210] Fig. 20A shows the 5' UTR nucleotide sequence of the mRNA of human
heat shock
protein family A (Hsp70) member 1A, also referred to as HSPA1A (GenBank entry
NM_005345.5).
[00211] Fig. 20B shows the 3' UTR nucleotide sequence of the mRNA of human
HSPA1A.
[00212] Fig. 21A shows the 5' UTR nucleotide sequence of the mRNA of human
heat shock
protein family A (Hsp70) member 5, also referred to as HSPA5, (GenBank entry
NM_005347.4).
[00213] Fig. 21B shows both the nucleotide sequence and the amino acid
sequence of the signal
sequence of the mRNA of human HSPA5.
[00214] Fig. 21B shows both the nucleotide sequence and the amino acid
sequence of the signal
sequence of the mRNA of human HSPA5.
[00215] Fig. 21C shows the 3' UTR nucleotide sequence of the mRNA of human
HSPA1A.
[00216] Fig. 22A shows the 5' UTR nucleotide sequence of the mRNA of human H3
histone
family member 3A (H3F3A), also referred to as H3.3, (GenBank entry
NM_002107.4).
53
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00217] Fig. 22B shows the 3' UTR nucleotide sequence of the mRNA of human
H3.3.
[00218] Fig. 23A shows the 5' UTR nucleotide sequence of the mRNA of human
galectin-9
(LGALS9), transcript variant 1 (GenBank entry NM_009587.2).
[00219] Fig. 23B shows the 3' UTR nucleotide sequence of the mRNA of human
galectin-9.
[00220] Fig. 24 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN01.
[00221] Fig. 25 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN03.
[00222] Fig. 26 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN04.
[00223] Fig. 27 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN06.
[00224] Fig. 28 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN36.
[00225] Fig. 29 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN37.
[00226] Fig. 30 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN02.
[00227] Fig. 31 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN05.
[00228] Fig. 32 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN07.
54
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00229] Fig. 33 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN08.
[00230] Fig. 34 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN09.
[00231] Fig. 35 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN10.
[00232] Fig. 36 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN11.
[00233] Fig. 37 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN12.
[00234] Fig. 38 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN13.
[00235] Fig. 39 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN28.
[00236] Fig. 40 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN29.
[00237] Fig. 41 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN30.
[00238] Fig. 42 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN31.
[00239] Fig. 43 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN32.
[00240] Fig. 44 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN33.
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00241] Fig. 45 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN34.
[00242] Fig. 46 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN35.
[00243] Fig. 47 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN38.
[00244] Fig. 48 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN39.
[00245] Fig. 49 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN40.
[00246] Fig. 50 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN41.
[00247] Fig. 51 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN42.
[00248] Fig. 52 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN43.
[00249] Fig. 53 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN44.
[00250] Fig. 54 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN45.
[00251] Fig. 55 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN46.
[00252] Fig. 56 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN47.
[00253] Fig. 57 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN48.
56
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00254] Fig. 58 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN49.
[00255] Fig. 59A shows the nucleotide sequence of mRNA of human angiopoietin
1, also
referred to as ANGPT1 or Ang-1, transcript variant 1, GenBank entry
NM_001146.4.
[00256] Fig. 59B shows both the nucleotide sequence and the amino acid
sequence of the
mRNA of human Ang-1.
[00257] Fig. 59C shows the coding sequence (CDS) of the mature peptide of mRNA
of human
Ang- 1.
[00258] Fig. 59D shows the 3' UTR nucleotide sequence of the mRNA of human Ang-
1.
[00259] Fig. 60A shows the nucleotide sequence of mRNA of human angiopoietin
4, also
referred to as ANGPT4 or Ang-4, transcript variant 1, GenBank entry
NM_015985.3.
[00260] Fig. 60B shows both the nucleotide sequence and the amino acid
sequence of the
mRNA of human Ang-4.
[00261] Fig. 60C shows the coding sequence (CDS) of the mature peptide of mRNA
of human
Ang-4.
[00262] Fig. 60D shows the 3' UTR nucleotide sequence of the mRNA of human Ang-
4.
[00263] Fig. 61 shows the nucleotide sequence coding for COMP-Ang 1 which is a
synthetic
construct.
[00264] Fig. 62 shows the nucleotide sequence coding for hCOMP-Ang 1 which is
a synthetic
construct.
[00265] Fig. 63 shows the nucleotide sequence coding for CMP-Ang 1 which is a
synthetic
construct.
[00266] Fig. 64 shows the nucleotide sequence coding for COMP-Ang2 which is a
synthetic
construct.
57
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00267] Fig. 65 shows the coding nucleotide sequence of mRNA of human TEK
receptor
tyrosine kinase (TEK), transcript variant 1, also referred to as Tie-2,
GenBank entry.
[00268] Fig. 66 shows the coding nucleotide sequence of mRNA of human mutant
TEK
receptor tyrosine kinase (TEK), which is also referred to as TIE* having a
R849W mutation.
[00269] Fig. 67 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN50.
[00270] Fig. 68 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN51.
[00271] Fig. 69 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN52.
[00272] Fig. 70 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN53.
[00273] Fig. 71A is an image of a non-denaturing agarose gel after EtBr
staining showing the
tail-PCR products of various construct.
[00274] Fig. 71B is an image of a non-denaturing agarose gel after EtBr
staining showing the
in vitro mRNA transcripts of various construct.
[00275] Fig. 72 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HPMEC where luciferase is used as the effector molecule after 2 hours (left
column), 6 hours
(middle column) and 24 hours (right column) post transfection.
[00276] Fig. 73 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in whole cell lysates of HPMEC, by the indicated
recombinant nucleic
acid constructs in HPMEC, where luciferase is used as the effector molecule
after 6 hours (left
column) and 24 hours (right column) post transfection.
[00277] Fig. 74A (left) is a bar diagram showing expression of luciferase,
indicated as RLU
(relative light units) of luciferase in medium, by the indicated recombinant
nucleic acid
constructs in HPMEC (transfected with GFP mRNA, PAN12 mRNA and PAN12* mRNA)
58
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
where luciferase is used as the effector molecule after 2 hours (left column),
6 hours (middle
column) and 24 hours (right column) post transfection. In PAN12* 100% of
uridine and 100%
cytidine nucleotides are replaced by pseudo-uridine and 5-methyl-cytidine,
respectively.
[00278] Fig. 74B (right) is a bar diagram showing expression of luciferase,
indicated as RLU
(relative light units) of luciferase in cell lysates, by the indicated
recombinant nucleic acid
constructs in HPMEC (transfected with GFP mRNA, PAN12 mRNA and PAN12* mRNA)
where luciferase is used as the effector molecule after 6 hours (left column)
and 24 hours (right
column) post transfection. In PAN12* 100% of uridine and 100% cytidine
nucleotides are
replaced by pseudo-uridine and 5-methyl-cytidine, respectively.
[00279] Fig. 75 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HPMEC where luciferase is used as the effector molecule after 1 hour, 2 hours,
4 hours and 24
hours post transfection (from left to right, with 1 hour results being shown
to the utmost left
side and 24 hours result being shown to the utmost right side).
[00280] Fig. 76 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in whole cell lysates of HPMEC, by the indicated
recombinant nucleic
acid constructs in HPMEC, where luciferase is used as the effector molecule
after 1 hour, 2
hours, 4 hours and 24 hours post transfection (from left to right, with 1 hour
results being shown
to the utmost left side and 24 hours result being shown to the utmost right
side).
[00281] Fig. 77A (left) is a bar diagram showing expression of luciferase,
indicated as RLU
(relative light units) of luciferase in medium, by the indicated recombinant
nucleic acid
constructs in HPMEC (transfected with GFP mRNA, PAN12 mRNA and PAN12* mRNA)
where luciferase is used as the effector molecule after 1 hour, 2 hours, 4
hours and 24 hours
post transfection (from left to right, with 1 hour results being shown to the
utmost left side and
24 hours result being shown to the utmost right side). In PAN12* 100% of
uridine and 100%
cytidine nucleotides are replaced by pseudo-uridine and 5-methyl-cytidine,
respectively.
[00282] Fig. 77B (right) is a bar diagram showing expression of luciferase,
indicated as RLU
(relative light units) of luciferase in cell lysates, by the indicated
recombinant nucleic acid
constructs in HPMEC (transfected with GFP mRNA, PAN12 mRNA and PAN12* mRNA)
where luciferase is used as the effector molecule after 1 hour, 2 hours, 4
hours and 24 hours
post transfection (from left to right, with 1 hour results being shown to the
utmost left side and
59
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
24 hours result being shown to the utmost right side). In PAN12* 100% of
uridine and 100%
cytidine nucleotides are replaced by pseudo-uridine and 5-methyl-cytidine,
respectively.
[00283] Fig. 78 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HPAEC where luciferase is used as the effector molecule after 1 hour, 2 hours,
4 hours and 24
hours post transfection (from left to right, with 1 hour results being shown
to the utmost left
side and 24 hours result being shown to the utmost right side).
[00284] Fig. 79 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in whole cell lysates of HPAEC, by the indicated
recombinant nucleic
acid constructs in HPAEC, where luciferase is used as the effector molecule
after 1 hour, 2
hours, 4 hours and 24 hours post transfection (from left to right, with 1 hour
results being shown
to the utmost left side and 24 hours result being shown to the utmost right
side).
[00285] Fig. 80 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HeLa cells where luciferase is used as the effector molecule after 1 hour, 2
hours, 4 hours and
24 hours post transfection (from left to right, with 1 hour results being
shown to the utmost left
side and 24 hours result being shown to the utmost right side).
[00286] Fig. 81 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in whole cell lysates of HeLa cells, by the
indicated recombinant
nucleic acid constructs in HeLA cells, where luciferase is used as the
effector molecule after 1
hour, 2 hours, 4 hours and 24 hours post transfection (from left to right,
with 1 hour results
being shown to the utmost left side and 24 hours result being shown to the
utmost right side).
[00287] Fig. 82 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HPMEC where luciferase is used as the effector molecule after 2 hours, 4
hours, 6 hours and
24 hours post transfection (from left to right, with 1 hour results being
shown to the utmost left
side and 24 hours result being shown to the utmost right side). In constructs
PAN12*, PAN28*,
PAN29*, PAN34*, PAN50* and PAN51*100% of uridine and 100% cytidine nucleotides
are
replaced by pseudo-uridine and 5-methyl-cytidine, respectively.
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00288] Fig. 83 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in whole cell lysates of HPMEC, by the indicated
recombinant nucleic
acid constructs in HPMEC, where luciferase is used as the effector molecule
after 2 hours, 4
hours, 6 hours and 24 hours post transfection (from left to right, with 1 hour
results being shown
to the utmost left side and 24 hours result being shown to the utmost right
side). In constructs
PAN12*, PAN28*, PAN29*, PAN34*, PAN50* and PAN51*100% of uridine and 100%
cytidine nucleotides are replaced by pseudo-uridine and 5-methyl-cytidine,
respectively.
[00289] Fig. 84 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HPMEC where luciferase is used as the effector molecule after 2 hours (left
column), 4 hours
(middle column) and 6 hours (right column) post transfection. In construct
PANO2*, 100% of
uridine and 100% cytidine nucleotides are replaced by pseudo-uridine and 5-
methyl-cytidine,
respectively; and in construct PAN51 w/o CAP the mRNA sequence is the one of
construct
PAN51, but without any 5' -capping structure.
[00290] Fig. 85 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in whole cell lysates of HPMEC, by the indicated
recombinant nucleic
acid constructs in HPMEC, where luciferase is used as the effector molecule
after 2 hours (left
column) 4 hours (middle column) and 6 hours (right column) post transfection.
In construct
PANO2*, 100% of uridine and 100% cytidine nucleotides are replaced by pseudo-
uridine and
5-methyl-cytidine, respectively; and in construct PAN51 w/o CAP the mRNA
sequence is the
one of construct PAN51, but without any 5' -capping structure.
[00291] Fig. 86 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN54.
[00292] Fig. 87 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN55.
[00293] Fig. 88 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN56.
[00294] Fig. 89 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN57.
61
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00295] Fig. 90 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN58.
[00296] Fig. 91 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN59.
[00297] Fig. 92 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HPMEC, where luciferase is used as the effector molecule after 4 hours (left
column).
Additional 4-hours luciferase activity values are assessed 24 hours (middle
column) and 48
hours (right column) post transfection, after washing of the cells and
supplementing the cells
with fresh medium.
[00298] Fig. 93 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HEK293 cells, where luciferase is used as the effector molecule after 3 hours
(left column). An
additional 3-hours luciferase activity value is assessed 24 hours (right
column) post
transfection, after washing of the cells and supplementing the cells with
fresh medium.
The human embryonic kidney 293 cell line (HEK293) is grown in EMEM (EBSS) +
2mM
Glutamine + 1% Non Essential Amino Acids (NEAA) + 10% FCS culture medium.
Subculture
Routine is to split sub-confluent cultures (70-80%) 1:2 to 1:6 i.e. seeding at
2-5x10,000
cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37 C. mRNA transfection
are
performed with the LipofectamineTM MessengerMAXTm Transfection Reagent
(InvitrogenTM)
according to the manufactures protocol.
[00299] Fig. 94 is a bar diagram showing expression of luciferase, indicated
as RLU (relative
light units) of luciferase in medium, by the indicated recombinant nucleic
acid constructs in
HeLa cells, where luciferase is used as the effector molecule after 3 hours
(left column). An
additional 3-hours luciferase activity value is assessed 24 hours (right
column) post
transfection, after washing of the cells and supplementing the cells with
fresh medium.
[00300] Fig. 95 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN60.
62
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00301] Fig. 96 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN61.
[00302] Fig. 97 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN66.
[00303] Fig. 98 shows Western Blot analysis of protein lysates from HPMEC
cells transfected
with indicated PAN mRNA constructs. Cells were transfected with 1 jug the
mRNAs and
harvested after 6 hours. Total cell lysates were separated by SDS-PAGE and
analyzed by
immunoblot using anti-Angl antibody. M, Marker; UT, untreated cells, rec.
Angl, recombinant
hAngl.
[00304] Fig. 99 shows Agarose gels of mRNAs after in vitro transcription. 2
jug of indicated
mRNAs were separated by agarose gel electrophoresis and visualized by ethidium
bromide
staining and UV illumination.
[00305] Fig. 100 shows the sequences of: a) the 5'UTR of PAN57; b) the 3'UTR
of PAN57;
c) the 5'PCR-Primer for PAN57; d) the 3'PCR-Primer for PAN57 and e) the 5' PCR-
Primer for
PAN55, PAN56.
[00306] Fig. 1 is a schematic representation of conventional mRNA molecule
structure.
Eukaryotic including mammalian mRNAs consist of a cap region, a 5'
untranslated region
(UTR), the coding sequence (CDS) with an open reading frame (ORF) starting
with a consensus
Kozak sequence for optimal translation initiation and in case of secreted
proteins followed by
an signal peptide leader sequences, a 3' UTR, and a poly A-tail (>120 nt) at
the 3' end.
[00307] Fig. 2 is a schematic representation of selected examples for mRNA
constructs with
the coding sequence with an open reading frame being the one of Nano-
luciferase. It is within
the present invention that for each and any of the indicated mRNA constructs
the coding region
comprising a sequence with an open reading frame for Nano-luciferase may be
replaced by a
coding regions comprising a sequence coding for an effector molecule,
particularly by a coding
region comprising a sequence coding for an effector molecule disclosed herein;
in a preferred
embodiment thereof, the effector molecule is Angl or COMP-Angl. In accordance
with the
present invention, the recombinant nucleic acid constructs are designed as
follows:
63
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00308] Recombinant nucleic acid construct PANO2 comprises as the 5' non-
translated region
the 5' UTR of Angl, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of Angl, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of Angl.
[00309] Recombinant nucleic acid construct PANO5 comprises as the 5' non-
translated region
the 5' UTR of Ang2, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of Ang2, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
[00310] Recombinant nucleic acid construct PANO7 comprises as the 5' non-
translated region
the 5' UTR of Galectin-9, as the nucleic acid sequence coding for a signal
peptide the nucleic
acid sequence coding for a signal peptide of Ang2, as the coding region coding
for an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
[00311] Recombinant nucleic acid construct PANO8 comprises as the 5' non-
translated region
the 5' UTR of Hsp70, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of Ang2, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of HSP70.
[00312] Recombinant nucleic acid construct PANO9 comprises as the 5' non-
translated region
the 5' UTR of H3.3, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of Ang2, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of H3.3.
[00313] Recombinant nucleic acid construct PAN10 comprises as the 5' non-
translated region
the 5' UTR of RPL12s.c., as the nucleic acid sequence coding for a signal
peptide the nucleic
acid sequence coding for a signal peptide of Ang2, as the coding region coding
for an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of RPL12s.c. This construct additionally comprises another start codon
preceding the
start codon of the coding region for Nano-luciferase in-frame.
64
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00314] Recombinant nucleic acid construct PAN11 comprises as the 5' non-
translated region
the 5' UTR of GADD34, as the nucleic acid sequence coding for a signal peptide
the nucleic
acid sequence coding for a signal peptide of Ang2, as the coding region coding
for an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of GADD34.
[00315] Recombinant nucleic acid construct PAN12 comprises as the 5' non-
translated region
the 5' UTR of MCP-1 as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of MCP-1.
[00316] Recombinant nucleic acid construct PAN13 comprises as the 5' non-
translated region
the 5' UTR of EDN1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of EDN1, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of EDN1.
[00317] Recombinant nucleic acid construct PAN28 comprises as the 5' non-
translated region
the 5' UTR of Ang2, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of IL-6, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of vWF.
[00318] Recombinant nucleic acid construct PAN29 comprises as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
[00319] Recombinant nucleic acid construct PAN30 comprises as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of HSP70.
[00320] Recombinant nucleic acid construct PAN31 comprises as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of IL-6, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of MCP-1.
[00321] Recombinant nucleic acid construct PAN32 comprises as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of Ang2, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of MCP-1.
[00322] Recombinant nucleic acid construct PAN33 comprises as the 5' non-
translated region
the 5' UTR of MCP-1, no nucleic acid sequence coding for a signal peptide, as
the coding
region coding for an effector molecule the coding region coding for Nano
luciferase, and as the
3' non-translated region the 3' UTR of MCP-1.
[00323] Recombinant nucleic acid construct PAN34 comprises as the 5' non-
translated region
the 5' UTR of Hsp70, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of MCP-1.
[00324] Recombinant nucleic acid construct PAN35 comprises as the 5' non-
translated region
the 5' UTR of RPL12 s.c. (spinach chloroplast), as the nucleic acid sequence
coding for a signal
peptide the nucleic acid sequence coding for a signal peptide of MCP-1, as the
coding region
coding for an effector molecule the coding region coding for Nano luciferase,
and as the 3' non-
translated region the 3' UTR of MCP-1.
[00325] Recombinant nucleic acid construct PAN36 comprises as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
66
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
molecule the coding region coding for Angl, and as the 3' non-translated
region the 3' UTR of
MCP-1.
[00326] Recombinant nucleic acid construct PAN37 comprises as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for hCOMP-Ang 1 , and as the 3' non-
translated region the
3' UTR of MCP-1.
[00327] Recombinant nucleic acid construct PAN38 comprises as the 5' non-
translated region
the 5' UTR of Ang2, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
[00328] Recombinant nucleic acid construct PAN39 comprises as the 5' non-
translated region
the 5' UTR of Ang2* (Ang2 5' -UTR with deleted upstream ATGs), as the nucleic
acid sequence
coding for a signal peptide the nucleic acid sequence coding for a signal
peptide of IL-6, as the
coding region coding for an effector molecule the coding region coding for
Nano luciferase,
and as the 3' non-translated region the 3' UTR of von Willebrand Factor (vWF).
[00329] Recombinant nucleic acid construct PAN40 comprises as the 5' non-
translated region
the 5' UTR of Ang2, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of Gaussia luciferase, as the coding
region coding for an
effector molecule the coding region coding for Nano luciferase, and as the 3'
non-translated
region the 3' UTR of von Willebrand Factor (vWF).
[00330] Recombinant nucleic acid construct PAN41 comprises as the 5' non-
translated region
the 5' UTR of RPL12 s.c., as the nucleic acid sequence coding for a signal
peptide the nucleic
acid sequence coding for a signal peptide of MCP-1 with an additional upstream
ATG for
translational start, as the coding region coding for an effector molecule the
coding region coding
for Nano luciferase, and as the 3' non-translated region the 3' UTR of RPL12
s.c.. This
construct additionally comprises another start codon preceding the start codon
of the coding
region for Nano-luciferase in-frame.
67
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00331] Recombinant nucleic acid construct PAN42 comprises as the 5' non-
translated region
the 5' UTR of RPL12 s.c., as the nucleic acid sequence coding for a signal
peptide the nucleic
acid sequence coding for a signal peptide of MCP-1, as the coding region
coding for an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of RPL12 s.c..
[00332] Recombinant nucleic acid construct PAN43 comprises as the 5' non-
translated region
the 5' UTR of RPL12 s.c., as the nucleic acid sequence coding for a signal
peptide the nucleic
acid sequence coding for a signal peptide of Ang2, as the coding region coding
for an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of RPL12 s.c..
[00333] Recombinant nucleic acid construct PAN44 comprises as the 5' non-
translated region
the 5' UTR of Hsp70, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of Hsp70.
[00334] Recombinant nucleic acid construct PAN45 comprises as the 5' non-
translated region
the 5' UTR of Hsp70m5, as the nucleic acid sequence coding for a signal
peptide the nucleic
acid sequence coding for a signal peptide of MCP-1, as the coding region
coding for an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
[00335] Recombinant nucleic acid construct PAN46 comprises as the 5' non-
translated region
the 5' UTR of E-selectin, as the nucleic acid sequence coding for a signal
peptide the nucleic
acid sequence coding for a signal peptide of IL-6, as the coding region coding
for an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
[00336] Recombinant nucleic acid construct PAN47 comprises as the 5' non-
translated region
the 5' UTR of ICAM1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of IL-6, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
68
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00337] Recombinant nucleic acid construct PAN48 comprises as the 5' non-
translated region
the 5' UTR of IL-6, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of IL-6, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of IL-6).
[00338] Recombinant nucleic acid construct PAN49 comprises as the 5' non-
translated region
the 5' UTR of von Willebrand Factor (vWF), as the nucleic acid sequence coding
for a signal
peptide the nucleic acid sequence coding for a signal peptide of von
Willebrand Factor (vWF),
as the coding region coding for an effector molecule the coding region coding
for Nano
luciferase, and as the 3' non-translated region the 3' UTR of von Willebrand
Factor (vWF).
[00339] Fig. 3 shows a restriction map of a plasmid pcDNA3.1(-) used as an
illustrative
example for a plasmid for the expression of an exemplary recombinant nucleic
acid construct
of the present invention, whereby such exemplary recombinant nucleic acid
construct is
construct PAN 11; restriction sites XhoI/HindIII are shown.
[00340] Fig. 4 shows a restriction digestion map of the PAN11 expressing
pcDNA3.1- plasmid
of Fig. 3; the insert represents PAN11 sequence with engineered 5' and 3' UTR,
signal sequence
and the coding region coding for Nano-Luciferase.
[00341] Fig. 5 is an 1% agarose gel stained with EtBr showing the non-
linearized (uncut,
supercoiled, right lanes) and linearization product (left lanes) of pcDNA3.1(-
) plasmids upon
BamHI restriction of the constructs PAN28 ("28"), PAN13 ("13"), PAN12 ("12"),
PAN11
("11"), PAN10 ("10"), PANO9 ("09"), PANO8 ("08"), PANO7 ("07") and PANO5
("05").
[00342] Fig. 6 shows 1% agarose gels stained with EtBr showing PCR products of
Poly-A
tailing PCRs for the addition of 120 nt of Poly-A tail by 120 nt long poly-T
3' primer flanking
the different recombinant nucleic acid constructs. On top are the optimized
PCR conditions for
the indicated recombinant nucleic acid constructs. For example, for Pan02 the
conditions are as
follows: denaturation for 2 minutes at 94 C. 33 cycles of 30 seconds at 96 C,
15 seconds at
55 C and 4 minutes at 72 C. Final extension for 8 minutes at 72 C.
[00343] Fig. 8 is an image of a 1% non-denaturing agarose gel stained with
EtBr showing the
in vitro transcribed mRNAs of constructs PAN28 ("28"), PAN13 ("13"), PAN12
("12"),
PAN11 ("11"), PAN10 ("10"), PANO9 ("09"), PANO8 ("08"), PANO7 ("07") and PANO5
69
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
("05"). M: is a lane with a high range RiboRuler RNA ladder. From this Fig. 8
may be taken
that the transcribed mRNAs were intact and, more specifically, were not
degraded.
[00344] Fig. 24 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN01. PAN1 is an embodiment of the present invention comprising as
the 5' non-
translated region the 5' UTR of Angl, as the nucleic acid sequence coding for
a signal peptide
the nucleic acid sequence coding for a signal peptide of Angl, as the coding
region coding for
an effector molecule the coding region coding for Angl, and as the 3' non-
translated region the
3' UTR of Angl.
[00345] Fig. 25 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN03. PANO3 is an embodiment of the present invention comprising as
the 5' non-
translated region the 5' UTR of Angl, as the nucleic acid sequence coding for
a signal peptide
the nucleic acid sequence coding for a signal peptide of Angl, as the coding
region coding for
an effector molecule the coding region coding for COMP-Ang 1, and as the 3'
non-translated
region the 3' UTR of Angl.
[00346] Fig. 26 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN04. PANO4 is an embodiment of the present invention comprising as
the 5' non-
translated region the 5' UTR of Ang2, as the nucleic acid sequence coding for
a signal peptide
the nucleic acid sequence coding for a signal peptide of Ang2, as the coding
region coding for
an effector molecule the coding region coding for Angl, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
[00347] Fig. 27 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN06. PANO6 is an embodiment of the present invention comprising as
the 5' non-
translated region the 5' UTR of Ang2, as the nucleic acid sequence coding for
a signal peptide
the nucleic acid sequence coding for a signal peptide of Ang2, as the coding
region coding for
an effector molecule the coding region coding for COMP-Ang 1, and as the 3'
non-translated
region the 3' UTR of von Willebrand Factor (vWF).
[00348] Fig. 28 shows the basic structure and nucleotide sequence of
recombinant nucleic acid
construct PAN36. PAN36 is an embodiment of the present invention comprising as
the 5' non-
translated region the 5' UTR of MCP-1, as the nucleic acid sequence coding for
a signal peptide
the nucleic acid sequence coding for a signal peptide of MCP-1, as the coding
region coding
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
for an effector molecule the coding region coding for Angl, and as the 3' non-
translated region
the 3' UTR of MCP-1.
[00349] Fig. 67 shows recombinant nucleic acid construct PAN50 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of IL-6, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
[00350] Fig. 68 shows recombinant nucleic acid construct PAN51 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of HSP70, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of IL-6, as the coding region coding for
an effector
molecule the coding region coding for Nano luciferase (NLuc), and as the 3'
non-translated
region the 3' UTR of von Willebrand Factor (vWF).
[00351] Fig. 69 shows recombinant nucleic acid construct PAN52 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for Angl, and as the 3' non-translated
region the 3' UTR of
von Willebrand Factor (vWF).
[00352] Fig. 70 shows recombinant nucleic acid construct PAN53 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for hCOMP-Ang 1, and as the 3' non-
translated region the
3' UTR of von Willebrand Factor (vWF).
[00353] Fig. 71A is an image of a 1% non-denaturing agarose gel stained with
EtBr showing
the tail-PCR products of constructs PAN35 ("35"), PA34 ("34"), PAN33 ("33"),
PAN32
("32"), PAN31 ("31"), PAN30 ("30"), PAN29 ("29") and PAN12 ("12"). M: is a
lane with a
high range RiboRuler RNA ladder. From this Fig. 71A may be taken that the
transcribed
mRNAs were intact and, more specifically, were not degraded.
71
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00354] Fig. 71B is an image of a 1% non-denaturing agarose gel stained with
EtBr showing
the in vitro mRNA transcripts of constructs PAN35 ("35"), PA34 ("34"), PAN33
("33"),
PAN32 ("32"), PAN31 ("31"), PAN30 ("30"), PAN29 ("29") and PAN12 ("12"). M: is
a lane
with a high range RiboRuler RNA ladder. From this Fig. 71B may be taken that
the transcribed
mRNAs were intact and, more specifically, were not degraded.
[00355] Fig. 86 shows recombinant nucleic acid construct PAN54 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of RPL12s.c. as the nucleic acid sequence coding for a signal
peptide the nucleic
acid sequence coding for a signal peptide of MCP-1, as the coding region
coding for an effector
molecule the coding region coding for Nano-Luciferase (NLuc), and as the 3'
non-translated
region the 3' UTR of von Willebrand Factor (vWF).
[00356] Fig. 87 shows recombinant nucleic acid construct PAN55 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of vWF, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for Nano Luciferase (NLuc), and as the 3'
non-translated
region the 3' UTR of von Willebrand Factor (vWF).
[00357] Fig. 88 shows recombinant nucleic acid construct PAN56 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of vWF, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of vWF, as the coding region coding for
an effector
molecule the coding region coding for Nano Luciferase (NLuc), and as the 3'
non-translated
region the 3' UTR of von Willebrand Factor (vWF).
[00358] Fig. 89 shows recombinant nucleic acid construct PAN57 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region a
synthetic nucleic acid sequence as described in Jiang, Lei et al. (2018).
Systemic messenger
RNA as an etiological treatment for acute intermittent porphyria. Nature
Medicine. 24, 1899-
2909 (2018) , as the nucleic acid sequence coding for a signal peptide the
nucleic acid sequence
coding for a signal peptide of MCP-1, as the coding region coding for an
effector molecule the
coding region coding for Nano Luciferase (NLuc), and as the 3' non-translated
region the 3'
UTR a nucleic acid sequence as described in Jiang, Lei et al. (2018). Systemic
messenger RNA
72
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
as an etiological treatment for acute intermittent porphyria. Nature Medicine.
24; 1899-1909
(2018). The 5' -and 3' sequences are shown underlined and in bold.
[00359] Fig. 90 shows recombinant nucleic acid construct PAN58 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for Nano Luciferase (NLuc), and as the 3'
non-translated
region the 3' UTR of von Willebrand Factor (vWF). In addition, PAN58 comprises
a consensus
Kozak sequence (GCCACC) in the six bases upstream of the start AUG.
[00360] Fig. 91 shows recombinant nucleic acid construct PAN59 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of MCP-1, as the nucleic acid sequence coding for a signal peptide
the nucleic acid
sequence coding for a signal peptide of MCP-1, as the coding region coding for
an effector
molecule the coding region coding for CMP-Ang 1, and as the 3' non-translated
region the 3'
UTR of von Willebrand Factor (vWF).
[00361] Fig. 95 shows recombinant nucleic acid construct PAN60 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of MCP-1, as the coding region coding for an effector molecule the
coding region
coding for wild type (wt) Tie2, and as the 3' non-translated region the 3' UTR
of von
Willebrand Factor (vWF).
[00362] Fig. 96 shows recombinant nucleic acid construct PAN61 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of MCP-1, as the coding region coding for an effector molecule the
coding region
coding for Tie2 mutant R849W , and as the 3' non-translated region the 3' UTR
of von
Willebrand Factor (vWF).
[00363] Fig. 97 shows recombinant nucleic acid construct PAN66 which is
another
embodiment of an mRNA of the present invention comprising as the 5' non-
translated region
the 5' UTR of MCP-1, as the coding region coding for an effector molecule the
coding region
coding for wild type PIK3CA which is, according to GenBank Homo sapiens
phosphatidylinosito1-4,5-bisphosphate 3-kinase catalytic subunit alpha
(PIK3CA) with the
73
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
respective reference number being 006218.4., and as the 3' non-translated
region the 3' UTR
of von Willebrand Factor (vWF).
The SEQ ID NOs: of the sequence listing are related to the instant disclosure
as summarized in
Table 1.
Table 1:
Seq ID Subject to Further information
No: Fig.
1 7A 5'Primer
2 7A 5'Primer
3 7A 5'Primer
4 7A 5'Primer
7A 5'Primer
6 7A 5'Primer
7 7A 5'Primer
8 7A 5'Primer
9 7A 5'Primer
7A 5'Primer
11 7B 3'Primer
12 7B 3'Primer
13 7B 3'Primer
14 7B 3'Primer
7B 3'Primer
16 7B 3'Primer
17 7B 3'Primer
18 7B 3'Primer
19 7B 3'Primer
15A 5 VTR MCP1
21 15B SP (signal peptide) nucleotide sequence of MCP1
22 15B SP amino acid sequence of MCP1
23 15C 3'UTR of MCP1
24 16A 5'UTR of RPL12
16B 3'UTR of RPL12
26 17A 5'UTR of Ang2
27 17B SP (signal peptide) nucleotide sequence of Ang2
28 17B SP (signal peptide) amino acid sequence of Ang2
29 17C 3'UTR of Ang2
18A 5'UTR of IL6
31 18B SP (signal peptide) nucleotide sequence of IL6
32 18B SP (signal peptide) amino acid sequence of IL6
33 18C 3'UTR of IL6
34 19A 5'UTR of vWF
19B SP(signal peptide) nucleotide sequence of vWF
74
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
Seq ID Subject to Further information
No: Fig.
36 19B SP (signal peptide) amino aicd sequence of vWF
37 19C 3'UTR of vWF
38 20A 5'UTR of HSP70 Al
39 20B 3'UTR of HSP70 Al
40 21A 5'UTR of HSP70 A5
41 21B SP (signal peptide) nucleotide sequence of HSP70 A5
42 21B SP (signal peptide) amino acid sequence of HSP70 A5
43 21C 3'UTR of HSP70 A5
44 22A 5'UTR of H3.3
45 22B 3'UTR of H3.3
46 23A 5'UTR of LGALS9
47 23B 3'UTR of LGALS9
48 24 Construct PANO1
49 25 Construct PANO3
50 26 Construct PANO4
51 27 Construct PANO6
52 28 Construct PAN36
53 29 Construct PAN37
54 30 Construct PANO2
55 31 Construct PANO5
56 32 Construct PANO7
57 33 Construct PANO8
58 34 Construct PANO9
59 35 Construct PAN10
60 36 Construct PAN11
61 37 Construct PAN12
62 38 Construct PAN13
63 39 Construct PAN28
64 40 Construct PAN29
65 41 Construct PAN30
66 42 Construct PAN31
67 43 Construct PAN32
68 44 Construct PAN33
69 45 Construct PAN34
70 46 Construct PAN35
71 47 Construct PAN38
72 48 Construct PAN39
73 49 Construct PAN40
74 50 Construct PAN41
75 51 Construct PAN42
76 52 Construct PAN43
77 53 Construct PAN44
78 54 Construct PAN45
79 55 Construct PAN46
80 56 Construct
81 57 Construct PAN48
82 58 Construct PAN49
CA 03108670 2021-02-03
WO 2020/030672
PCT/EP2019/071173
Seq ID Subject to Further information
No: Fig.
83 59A 5'UTR of Angl
84 59B SP (signal peptide) nucleotide sequence of Angl
85 59B SP (signal peptide) amino acid sequence of Ang 1
86 59C CDS of Ang 1 (mature peptide+stop codon)
87 Amino acid sequence derived from SEQ ID No. 86
88 59D 3'UTR of Angl
89 60A 5'UTR of Ang4
90 60B SP (signal peptide) nucleotide sequence of Ang4
91 60B SP (signal peptide) amino acid sequecne of Ang4
92 60C CDS of Ang4 (mature peptide+stop codon)
93 Amino acid sequence derived from SEQ ID No.92
94 60D 3'UTR of Ang4
95 61 COMP-Angl CDS (mature pep+stop codon) (rat)
96 Amino acid sequence derived from SEQ ID No.95
97 62 hCOMP-Angl CDS (mature pep+stop codon) (human)
98 Amino acid sequence derived from SEQ ID No.97
99 63 CMP-Ang 1 CDS (mat peptide+stop codon)
100 64 COMP-Ang2 CDS (mat peptide+stop codon)
101 65 Tie2 CDS (start+mat pep+stop codon)
102 Amino acid sequence derived from SEQ ID No.101
103 66 Tie2* CDS (R849W)(start+mat pep+stop codon)
104 Amino acid sequence derived from SEQ ID No.103
105 67 Construct PAN50
106 68 Construct PAN51
107 69 Construct PAN52
108 70 Construct PAN53
109 86 Construct PAN54
110 87 Construct PAN55
111 88 Construct PAN56
112 89 Construct PAN57 (Mod)
113 90 Construct PANS 8
114 91 Construct PAN59
115 95 Construct PAN60 (Tie2 wt)
116 96 Construct PAN61 (Tie2 R849W)
117 97 Construct PAN66 (PIK3CA wt)
118 Construct CDS (start+mat pep+stop codon) PIK3CA
119 CDS (mature peptide+stop cod) Nluc
120 100a 5'UTR of (PAN57)
121 100b 3'UTR of (PAN57)
122 7B 3'Primer for constructs PAN01-PANO3
123 100c 5'Primer for construct PAN57
124 100d 3'Primer for construct PAN57
125 100e 5'Primer for construct PAN55 (Fig. 87) and PAN56 (Fig 88)
76
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00364] Example 1: Materials and Methods
[00365] Plasmid Template generation by gene synthesis and cloning
[00366] Sequences encoding Nluc reporter protein, Ang-1 protein and
derivatives thereof
(e.g. COMP-Ang-1, CMP-Ang-1) with different signal peptides were flanked by
different
heterologous 5' and 3' UTRs and were designed and produced by gene synthesis
by BioCat
(Heidelberg) and cloned (Xhol¨BamHI) into pcDNA3.1- (Thermo Fisher).
[00367] Sequences encoding wt Tie-2 and sequences with the specified Tie-2
mutation in the
coding region flanked by different heterologous 5' and 3' UTRs were designed
(see Figures 95
and 96) and produced by gene synthesis by BioCat (Heidelberg) and cloned
(Xhol¨BamHI)
into pcDNA3.1- (Thermo Fisher).
[00368] In vitro transcription from PCR products to generate polyadenylated
mRNAs
[00369] In vitro transcription is the synthesis of RNA transcripts by RNA
polymerase from a
linear DNA template containing the corresponding promoter sequence (T7, T3,
5P6) and the
gene to be transcribed. A typical transcription reaction consists of the
template DNA, RNA
polymerase, ribonucleotide triphosphates, RNase inhibitor and buffer
containing Mg2+ ions.
Linearized plasmid DNA, PCR products and synthetic DNA oligonucleotides can be
used as
templates for transcription as long as they have the T7 promoter sequence
upstream of the gene
to be transcribed. In order to generate DNA templates with a poly-(A) tail a
tail-PCR using 5'
primers containing T7 RNA polymerase sequences and 3' primers with a 120 nt
Poly-T
sequence were synthesized and purified (BioSpring, Frankfurt).
[00370] The Linear DNA templates for in vitro transcription were generated by
PCR from
linearized plasmid. Plasmids were digested with BamHI that cut once 3-terminal
in the vector
backbone to produce a linearized vector that can be used as the template for
the poly-(A) tail
PCR. 5jug plasmid are digested for 2h at 37 C with 5U BamHI restriction enzyme
in 50 1 and
lx HF Buffer. Small Aliquots of digested mix were analyzed by gel
electrophoresis to check
for complete digestion of the plasmid (see, for example, Fig. 5 for constructs
PAN28 ("28"),
PAN13 ("13"), PAN12 ("12"), PAN11 ("11"), PAN10 ("10"), PANO9 ("09"), PANO8
("08"),
PANO7 ("07") and PANO5 ("05")). The restriction enzyme is heat-inactivated by
incubating at
77
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
80 C for 20 min and the digested plasmid is purified by a PCR purification
column following
the manufacturer's protocol (NucleoSpin Gel and PCR clean-up, Macherey-Nagel).
The
linearized plasmid can be stored at -20 C for several months and can be used
for PCR template
generation. The purpose of linearization was to eliminate circular templates
that could
potentially generate run-on transcripts during the IVT reaction.
[00371] Addition of poly-(A) tail by PCR was performed by using Hot
StarHiFidelity
polymerase (Qiagen) or Taq DNA Polymerase (Roche) following the manufacturer's
protocol.
For this purpose, Adapter primers containing T7 promoter sequences and 3' Poly
A tail
sequences (120nt) were used to amplify linear DNA-templates. Each of the
adapter primers had
overlap sequences which fused regulatory sequences necessary for translation
and transcription
to the gene of interest (see, for example, Figures 7a and 7b). A typical 50 1
PCR reaction
contained final concentrations of 2001jM (of each) dNTP, 0,51jM for each
primer, 50 ng
linearized plasmid DNA, lx PCR reaction buffer (1,5 mM MgCl2) and 1,25 U Taq
DNA
Polymerase per reaction (0,25 1 of 5U/ 1). The specific PCR cycle programs or
thermal profiles
were adjusted according to the Tm of the primer pairs, according to the
expected length of the
PCR product and according to the used thermal cycler. The quality of the PCR
products was
checked by analyzing an aliquot by gel electrophoresis and the reactions are
purified by
commercial PCR purification kits ((NucleoSpin Gel and PCR clean-up, Macherey-
Nagel).
[00372] In vitro transcription reaction
[00373] Addition of a 5' end cap structure to the RNA is an important process
in eukaryotes. It
is essential for RNA stability, efficient translation, nuclear transport and
splicing. The process
involved addition of a 7-methylguanosine cap at the 5' triphosphate end of the
RNA. RNA
capping can be carried out post-transcriptionally using capping enzymes or co-
transcriptionally
using cap analogs such as ARCA (Jena Bioscience) or CleanCap (Trilink
Biotechnologies) or
EZ-Cap (ApexBio). In the enzymatic method, the mRNA may be capped using the
vaccinia
virus mRNA capping enzyme (NEB) as per manufacturer's protocol. The enzyme
adds on a 7-
methylguanosine cap at the 5' end of the RNA using GTP and S-adenosyl
methionine as donors
(cap-0 structure). Both methods yield functionally active capped RNA suitable
for transfection
or other applications. In addition, a 2' -0-Methyltransferase can be used to
introduce cap-1 and
cap-2 structures.
78
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00374] In the example described below, the T7 High Yield Transcription Kit
(Thermo
Scientific) was used to synthesize capped RNA transcripts (PAN 01-XX) using
cap analogs co-
transriptionally.
[00375] The DNA template for the transcription reaction was a linearized
plasmid or a PCR
product. For the capped RNA the reaction at room temperature was set up in the
following
order:
FComponent 'volume ( 1)
'Nuclease free water* [To 20
I5X Reaction Buffer 4 I1X
'ATP (100 mM) 2 11 OrnM
CTP (100 mM) or m M
5' -Methylcytidine-5' -Triphophate (100 mM)
UTP (100 mM) or ¨
Pseudouridine-5' -Triphosphate (100 mM) or
2
10mM
5-Methoxyuridine-5' -Triphosphate (100 mM)
Ni-Methyl-pseudouridine (100mM)
1GTP (30 mM) __________________________________ 12 13mM
13'-0-Me-m7G(5')ppp(5')G cap analog (ARCA; Anti
2 FOmM
Reverse Cap Analog) (100 mM)
'Template DNA* X Fag
'T7 RNA Pol merase Mix 12
'Total =1
[00376] 1 tg DNA was added and the total reaction volume to 20 pJ was obtained
by adding
nuclease free water. The amount of water to be added varied based on the
concentration of the
template DNA. The reactions at were well mixed by vortexing and incubated at
37 C for 2
hours in a dry air incubator. The transcription reactions were treated with
DNase I to remove
the DNA template before proceeding with purification as follows:
1. 70 pJ nuclease free water was added to the transcription reactions followed
by 10 pJ of
DNase I reaction buffer.
2. 2 pJ DNase I were added to the reactions.
3. The reaction was incubated at 37 C for 15 minutes.
Column Purification of Capped mRNA
79
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
1. The capped RNA was purified using the MEGAclearKit as per the
manufacturer's
instructions (any spin column based RNA purification kit may be used).
2. The RNA was quantified using a NanoDrop Spectrophotometer.
3. As per the manufacturer's instructions, RNA sample quality was assessed
using the
Agilent RNA 6000 Nano Kit and Agilent 2100 Bioanalyzer or by native 1% agarose
gel
electrophoresis and ethidium bromide staining (see, Fig. 8).
[00377] mRNA transfection of HeLa cells, HEK293 cells, HPMEC cells, HPAEC
cells and
HUVEC cells
[00378] HeLa cells, were grown in DMEM complete medium. The human embryonic
kidney
293 cell line (HEK293) is grown in EMEM (EBSS) + 2mM Glutamine + 1% Non
Essential
Amino Acids (NEAA) + 10% FCS culture medium.
[00379] The human embryonic kidney 293 cell line (HEK293) is grown in EMEM
(EBSS) +
2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 10% FCS culture medium.
Subculture Routine is to split sub-confluent cultures (70-80%) 1:2 to 1:6 i.e.
seeding at 2-
5x10,000 cells/cm2 using 0.25% tryp sin or trypsin/EDTA; 5% CO2; 37 C. mRNA
transfection
are performed with the LipofectamineTM MessengerMAXTm Transfection Reagent
(InvitrogenTM) according to the manufactures protocol.
[00380] Primary Human Pulmonary Microvascular Endothelial Cells (HPMEC) and
Primary
Human Pulmonary Artery Endothelial Cells (HPAEC) are isolated from human
pulmonary
arteries are most appropriate for studying human lung diseases and are
isolated from the lung
from a single donor. Since lung tissue contains blood and lymphatic
capillaries, HPMEC
comprise Blood and Lymphatic Microvascular Endothelial Cells.
[00381] The cell type of HPMEC 's are characterized by immunofluorescent
staining. They
stain positive for CD31 and von Willebrand factor and negative for smooth
muscle alpha-actin.
[00382] HUVEC, HPAEC and HPMEC cells were grown in Endothelial Cell Growth
Medium
as recommended from PromoCell (Heidelberg Germany,) respectively. The
Endothelial Cell
Growth Medium is basal Medium supplemented with Fetal Calf Serum (0.05 ml/ml),
Endothelial Cell Growth Supplement (bovine hypothalamic extract; 0.004 ml ml),
Heparin
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
901.tg/m1 and Hydrocortisone 1 lAg/ml. The experiments with HUVEC, HPAEC and
HPMEC
cells are performed on cells with passage numbers below 8.
[00383] RNA transfections and more mRNA transfections were carried out using
Lipofectamin
MessengerMAX (Invitrogen, Carlsbad, CA; Thermo Fisher Scientific). . For mRNA
transfection in 24-well plate format 1 x105 cells/well were seeded 24h before
transfection to
reach 70-90 confluence immediately before transfection. For one single well
1.5 1
Lipofectamine MessengerMAX Reagent was added to 25 1 OptMEM (Invitrogen,
Carlsbad,
CA; Thermo Fisher Scientific), vortexed and incubated for 10 min at RT. In a
second well
500ng or liug mRNA were added to 25 1 OptiMEM, and vortexed. After incubation
diluted
mRNA was added to diluted Lipofectamin, mixed well, incubated for 5 min at RT
and added
dropwise to cells in the presence of 0,5 ml of complete medium for Hela and
HEK293. For
HUVEC, HPAEC and HPMEC the Endothelial Cell Growth medium was replaced and the
cells
washed with OptiMEM and then the Lipofectamin MessengerMAxX mRNA complex
solution
added to the well with 0,5 ml OptiMEM prewarmed to 37 C . Cells were
incubated at 37 C for
2h and the OptiMEM medium replaced with complete Endothelial Cell Growth
Medium
(PromoCell, Heidelberg Germany).
[00384] Cell Lysates from Transfected cells or serum were analyzed at the
indicated time
points. Alternatively, mRNA-LNPs based on the cationic lipids L-Arginy1-13-
alanine-N-
palmityl-N-oleyl-amide or 13-(L-Arginy1)-L-2,3-diamino propionic acid-N-
palmityl-N-oleyl-
amide in combination with neutral and PEGylated co-lipids were used for in
vitro transfection.
The co-lipids were Diphytanoyl-PE and the PEGylated lipid is methoxyPEG2000-
DSPE
[00385] Successful introduction of mRNA into host cells was monitored using
various known
methods, such as a fluorescent marker, such as Green Fluorescent Protein
(GFP), such as
reporter enzymes (e.g. luciferase derivatives). Alternatively, transfection of
a modified mRNA
could also be determined by measuring the protein expression level of the
target polypeptide
by e.g., Western Blotting or immunocytochemistry or ELISA.
[00386] Fully modified mRNAs with 5-methylcytidine and/or pseudouridine (or 5-
methoxyuridine or Ni-methylpseudouridine) are transfected into HUVEC or HPMEC
(Human
Pulmonary Microvascular Endothelial Cells, PromoCell, Heidelberg) using
Lipofectamin
MessengerMAX (Invitrogen, Carlsbad, CA; Thermo Fisher Scientific). The cell
lysates are
81
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
harvested and run by ELISA (or on immunoblot assays (western) at different
time points (30",
1 h, 2h, 4h, 6h hours) after transfection to determine the protein expression.
[00387] Nano-Luc Luciferase activity reporter measurement
[00388] A time dependent quantitative detection of Nano-Glo-Luciferase
expression
(Promega) was performed for secreted versions by analyzing samples from the
tissue culture
supernatant according to the reporter assay technical manual Nano-Glo
Luciferase Assay
System (Promega). In brief, 5-20 1 of serum or lysate were diluted in 100 1
H20 final volume
and equal volume of reconstituted Nano-Glo luciferase assay reagent was
combined in a 96
well GloMax 96 Microplate. After at least 3 min incubation at RT luminescence
were measured
in an appropriate luminometer.
[00389] Immunoblot detection of Tie-2 and derivates
[00390] For immunoblot detection of Tie-2 and derivatives protein lysates are
loaded on
NuPage SDS-PAGE system (chambers and power supply) with 1.5mm ready-to-use Bis-
Tris
gels and 4-12% acrylamide gradient with MOPS-buffer as running aid (all Life
Technologies,
Grand Island, NY). Each lysate sample is prepared to 40 jul final volume. This
sample contains
25 jug protein lysate in variable volume, RIPA buffer to make up volume to 26
I, 4 jul of 10x
reducing agent and 10 jul 4x SDS loading buffer (both from Life Technologies,
Grand Island,
NY). Samples are heated at 95 C for 5min and loaded on the gel. Standard
settings are chosen
by the manufacturer, 200V, 120mA and max. 25 W. Run time is 60min, but no
longer than
running dye reaching the lower end of the gel.
[00391] After the run is terminated, the plastic case is cracked and the
encased gel transferred
to a ready-to-use nitrocellulose membrane kit and power supply (iBLOT;
LifeTechnologies,
Grand Island, NY). Using default settings, the protein lysate is transferred
by high Ampere
electricity from the gel to the membrane.
[00392] After the transfer, the membranes are incubated in 5% BSA in IX TBS
for 15 minutes
then in 5% BSA in IX TBS + 0.1 % Tween for another 15 minutes. Primary
antibodies against
human Tie-2 proteins or Phospho-specific Antibodies (P-Tie-2, P-Akt, see
below) are applied
in 3m1 of 5% BSA in IX TBS solution at a 1:500 to 1:2000 dilution for 3 hours
at room
temperature and gentle agitation on an orbital shaker. Membranes are washed 3
times with IX
82
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
TBS/0.1 % Tween, 5 minutes each time with gentle agitation. The secondary
antibody (Goat
anti-rabbit HRP conjugate; Abeam, Cambridge, MA) is conjugated to horse radish
peroxidase
and binds to the primary antibody antibodies. The secondary antibody is
diluted from 1:1000
to 1:5000 in 5% BSA in IX TBS and incubated for 3 hrs at RT. At the end of
incubation time,
the membranes are washed 3 times with IX TBS/0.1 % Tween, 5 minutes each time
with gentle
agitation. The membranes are developed in 5m1 Pierce WestPico Chemiluminescent
Subtrate
(Thermo Fisher, Rockford, IL) as directed.
[00393] Example 2: Expression of luciferase, Ang-1 or Ang-l-derivatives
expressing
recombinant nucleic acid constructs in HPMEC, HUVEC, HPAEC and HeLa cells
[00394] mRNAtransfection of HeLa, HUVEC, HPAEC and HPMEC cells
[00395] Primary Human Pulmonary Microvascular Endothelial Cells (HPMEC) are
most
appropriate for studying human lung diseases and are isolated from the lung
from a single
donor. Since lung tissue contains blood and lymphatic capillaries, HPMEC
comprise Blood and
Lymphatic Microvascular Endothelial Cells. The cells were routinely analyzed
by
immunofluorescent staining: they stain positive for CD31 and von Willebrand
factor and
negative for smooth muscle alpha-actin. HeLa cells, HUVEC, HPMEC and HPAEC
(human
pulmonary artery endothelial cells) cells, respectively, were grown in DMEM
complete
medium or Endothelial Cell Growth Medium (PromoCell, Heidelberg Germany,
CatNo.: C-
22020) respectively. The Endothelial Cell Growth Medium was basal Medium
supplemented
with Fetal Calf Serum (0.05 ml/ml), Endothelial Cell Growth Supplement (bovine
hypothalamic extract; 0.004 ml ml), Heparin 90 g/m1 and Hydrocortisone 1 g/ml.
The
experiments with HUVEC and HPMEC cells were performed on cells with passage
numbers
below 8.
[00396] mRNA transfections were carried out using Lipofectamin MessengerMAX
(Invitrogen, Carlsbad, CA; Thermo Fisher Scientific). For mRNA transfection in
24-well plate
format 1x105 cells/well were seeded 24h before transfection to reach 70-90
confluence
immediate before transfection. For one single well 1.5 1 Lipofectamine
MessengerMAX
Reagent was added to 25 1 OptiMEM, vortex and incubated for 10 min at RT. In a
second well
add 500ng or 1 g mRNA were added to 25 1 OptiMEM, vortex. After incubation
diluted
83
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
mRNA was added to diluted Lipofectamin, mixed well, incubated for 5 min at RT
and added
dropwise to cells in the presence of 0,5 ml of DMEM complete medium for HeLa.
For HUVEC,
HPMEC and HPAEC the Endothelial Cell Growth medium was replaced and the cells
washed
with OptiMEM and then added the Lipofectamin MessengerMAX mRNA complex
solution to
the well with 0,5 ml OptiMEM prewarmed to 37 C. Cells were incubated at 37 C
for 2h and
the OptiMEM medium was replaced with complete Endothelial Cell Growth Medium
(PromoCell, Heidelberg Germany) and transfected cells or serum were analyzed
at the indicated
time points. Alternatively, mRNA-LNPs based on the cationic lipids L-Arginy1-
13-alanine-N-
palmityl-N-oleyl-amide or 13-(L-Arginy1)-L-2,3-diamino propionic acid-N-
palmityl-N-oleyl-
amide in combination with neutral and PEGylated co-lipids can be used for in
vitro transfection.
[00397] Successful introduction of mRNA into host cells can be monitored using
various
known methods, such as a fluorescent marker, such as Green Fluorescent Protein
(GFP), such
as reporter enzymes (e.g. luciferase derivatives) or transfection of a
modified mRNA can also
be determined by measuring the protein expression level of the target
polypeptide by e.g.,
Western Blotting or immunocytochemistry or ELISA.
[00398] Nano-Luc Luciferase activity reporter measurement
[00399] A time dependent quantitative detection of Nano-Glo-Luciferase
expression
(Promega) was performed for secreted versions by analyzing samples from the
tissue culture
supernatant according to the reporter assay technical manual Nano-Glo
Luciferase Assay
System (Promega). In brief, 5-20 1 of serum or lysate were diluted in 100 1
H20 final volume
and equal volume of reconstituted Nano-Glo luciferase assay reagent was
combined in a 96
well GloMax 96 Microplate. After at least 3 min incubation at RT luminescence
could be
measured in an appropriate luminometer.
[00400] Detection of Ang-1, COM-Ang-1, CMP-Ang-1 protein in cell lysates
and
supernatant
[00401] A time dependent quantitative detection of secreted Ang-1 and
secreted COMP-
Ang-1 or COMP-Ang-2 expression is performed by analyzing samples from the
supernatant
84
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
tissue culture by ELISA (Human Angiopoietin-1 Quantikine ELISA Kit (DANG10õ
R&D
systems) or by Western blot according to the technical manual.
[00402] 500 ng of COMP-Ang-1 (mRNA sequence shown in SEQ ID NO: PAN05) with
polyA tail of approximately 120 nucleotides not shown in sequence; 5 'cap,)
fully modified with
5-methylcytidine and pseudouridine (COMP-Ang-1, 5mC/pU), fully modified with 5-
methylcytidine and Nl-methyl-pseudouridine (COMP-Ang-1,5mC/NlmpU) or
unmodified
(COMP-Ang-, unmod) is transfected into HUVEC or HPMEC (Human Pulmonary
Microvascular Endothelial Cells, PromoCell, Heidelberg) using Lipofectamin
MessengerMAX
(Invitrogen, Carlsbad, CA; Thermo Fisher Scientific). The supernatant is
harvested and run by
ELISA 4 hours after transfection to determine the protein expression and
cytokine induction.
[00403] For immunoblot detection of Ang-1 and derivatives protein lysates
were loaded
on NuPage SDS-PAGE system (chambers and power supply) with 1.5mm ready-to-use
Bis-
Tris gels and 4-12% acrylamide gradient with MOPS-buffer as running aid (all
Life
Technologies, Grand Island, NY). Each lysate sample was prepared to 40u1 final
volume. This
sample contained 25ug protein lysate in variable volume, RIPA buffer to make
up volume to
26u1, 4u1 of 10x reducing agent and 10 1 4x SDS loading buffer (both from Life
Technologies,
Grand Island, NY). Samples were heated at 95oC for 5min and loaded on the gel.
Standard
settings were chosen by the manufacturer, 200V, 120mA and max. 25 W. Run time
was 60min,
but no longer than running dye reaching the lower end of the gel.
[00404] After the run is terminated, the plastic case is cracked and the
encased gel
transferred to a ready-to-use nitrocellulose membrane kit and power supply
(iBLOT;
LifeTechnologies, Grand Island, NY). Using default settings, the protein
lysate is transferred
by high Ampere electricity from the gel to the membrane.
[00405] After the transfer, the membranes were incubated in 5% BSA in IX
TBS for 15
minutes then in 5% BSA in IX TBS + 0.1 % Tween for another 15 minutes. Primary
antibodies
(Ang-1 ab183701 Abcam, Cambridge, UK) against human Ang-1 proteins are applied
in 3m1
of 5% BSA in IX TBS solution at a 1:5000 dilution overnight at 4 C and gentle
agitation on an
orbital shaker. Membranes are washed 3 times with 1X TBS/0.1 % Tween, 5
minutes each time
with gentle agitation. The secondary antibody (Goat anti-rabbit HRP conjugate;
Abeam,
Cambridge, MA) is conjugated to horse radish peroxidase and binds to the
primary antibody
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
antibodies. The secondary antibody is diluted of 1:10000 in 5% BSA in IX TBS
and incubated
for 1 hr at RT. At the end of incubation time, the membranes are washed 3
times with IX
TBS/0.1 % Tween, 5 minutes each time with gentle agitation. The membranes are
developed
in 5m1 Pierce WestPico Chemiluminescent Subtrate (Thermo Fisher, Rockford, IL)
as directed.
The Western Blot detects protein around the expected size of 70 kd for human
Ang-1, and of
37kDa for COMP-Ang-1 and CMP-Angl. For reference, recombinant human Ang-1
protein
was purchased from R&D Systems (biotechne).
[00406] Results
[00407] Protein expression data presented in the Figures 10 to 14, 72 to 85
and 92 to 94
underline that combinations of different regulatory nucleotide sequences
flanking a coding
region can significantly change the protein expression levels. Such change is
further impacted
by modification of the nucleotides forming the constructs as exemplified by
replacing 100% of
uridine and 100% cytidine nucleotides by pseudo-uridine and 5-methyl-cytidine
(the constructs
marked with "*" in Figure 74 and Figures 77 to 85. Changes are not only
observed in a
particular cell type but also across different cell types. For example, PANO2
(wild-type Ang-1
mRNA) shows the lowest Luciferase activity in all cell lines (Figures 10 to
14). All other
constructs show enhanced protein expressions throughout all cell types.
Therefore, the approach
of using regulatory sequences from different genes can increase protein
expression activity. To
this end, replacing the endogenous Ang-1 sequences have shown superior effects
on the protein
expression of the reporter.
[00408] Worth noting, even the same regulatory sequences showed distinct
protein
expression activity in different cell types (Figures 75 to 81. These data
further support our
approach that the use of specific regulatory sequences can influence the
activity of protein
expression in a context-specific, i.e. cell-type specific cellular
environment.
[00409] Furthermore, we have shown that our data are also concerning a
different aspect i.e.
secretion. For example, the regulatory sequences used in construct PAN12 show
cell-type
specific (HPMEC) expression in whole cell lysates but also in medium
(supernatant) (Figures
10-14). This indicated that these sequences are not only optimal for protein
expression
(translation) but also secretion. In contrast, construct PAN28 shows
expression in all cell types
more or less equally. The regulatory sequences used in construct PAN29 (and
PANS 8), namely
86
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
the 5' -UTR and the signal peptide sequence of MCP-1 in combination with the
3' -UTR of vWF,
were found to be particularly useful for highly efficient protein expression
in human
(microvascular) pulmonary endothelial cells (see e.g. Figures 72 and 75). The
regulatory
sequences used in construct PAN54, namely the 5' -UTR of spinach chloroplast
RPL12, the
signal peptide sequence of MCP-1 and the 3' -UTR of vWF, were found to be
equally efficient
for protein expression and secretion as shown in Figure 92.
As shown in Fig. 98 the regulatory sequences of PAN29 are also functional
using three different
ORFs, namely wt Ang-1 in PAN52; hCOMP-Ang-1 in PAN53 and CMP-Ang-1 in PAN59 in
directing expression in primary human pulmonary microendothelial cells
(HPMEC). In contrast
the mRNA construct containing the endogenous 5' -and 3' -UTRs of human Ang-1
(PAN01) is
not translated (Fig. 98). Fig. 99 shows that all four mRNA constructs display
comparable
quality (integrity and purity).
[00410] Example 3: Tie-2 pathway activation after transfection of modified
mRNAs
encoding the wildtype Tie-2 (PAN60) or the activating Tie-2 mutations (e.g.
R849W
(PAN61))
[00411] Modified mRNAs containing heterologous 5' and 3' UTRs are generated by
in vitro
transcription of PCR templates as described previously in example 1 above.
Different
concentration of this mRNA encoding the activating Tie-2 mutations (e.g.
R849W) are
transfected in different cell lines (HeLa, primary endothelial cells such as
HUVECs or HPMEC
or HPAEC) next to mRNAs encoding the wild-type Tie-2 using Lipofectamin
MessengerMAX
(Invitrogen, Carlsbad, CA; Thermo Fisher Scientific.). For qualitative Western
blot cell lysates
at different time points post transfection of mRNAs (1-24 h) are probed with
anti-
phosphotyrosine antibody (R&D systems) to evaluate Tie-2 phosphorylation
(pTyr, 140 kD,).
Blots are stripped and re-probed with anti-Tie-2 antibody (R&D systems) to
detect total Tie-2.
For quantitative measurement two different ELISAs are performed measuring
human Tie-2 or
Phospho-Tie-2 using the human Tie-2 DuoSet ELISA kit or human-Phospho-Tie-2
DuoSet IC
ELISA according to the manufactures (e.g. both ELISA-Kits from R&D systems)
protocol.
[00412] Transfection of Tie-2 mutation (PAN61, R849W) encoding mRNAs increase
the
presence of Phospho-Tie-2 in comparison to cell lysates derived from cells
transfected with
mRNAs encoding wildtype Tie-2 mRNA or in comparison to non-transfected cells.
This
87
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
increase in Tie-2 phosphorylation is observed in the presence or absence of co-
stimulation with
recombinant human Ang-1 ligand and can be observed in different cell lines. To
confirm the
activation of the Tie-2 signaling pathway and to demonstrate a biological
relevant functional
downstream signal transduction by expressing the Tie-2 (R849W) derivate a
phosphorylation
of Akt is demonstrated in a time course experiment. These experiments indicate
that mRNAs
encoding for the Tie-2 activating mutation (R849W) are functional and stronger
in activating
the Tie-2 signalling pathway than wt Tie-2 encoding mRNAs. These
hyperactivation of the
pathway can be demonstrated in the absence or presence of Tie-2 ligands (e.g.
Ang-1) in human
endothelial and/or non-endothelial cells.
[00413] Example 4: mRNA Formulation in cationic LNPs for in vivo
applications
by intravenous administration
[00414] For in vivo experiments mRNA-LNPs are prepared in a formulation
process with
13-(L-Arginy1)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide as
cationic lipid.
Alternatively, the cationic lipid L-Arginy1-13-alanine-N-palmityl-N-oleyl-
amide can be used in
an identical procedure to prepare mRNA-LNPs.
[00415] mRNA-LNP formulations are prepared using a modified procedure of a
method
described for siRNA (Chen, S., Tam, Y.Y., Lin, P.J., Sung, M.M., Tam, Y.K.,
and Cullis, P.R.
(2016), Influence of particle size on the in vivo potency of lipid
nanoparticle formulations of
siRNA. J. Control. Release 235, 236-244. & (ii) patent application
U520170121712).
[00416] Briefly, lipids are dissolved in ethanol at appropriate molar
ratios (e.g. 50:49:1
13-(L-arginy1)-L-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide: DPyPE:
mPEG2000-
DSPE). The lipid mixture is combined with an isotonic Sucrose solution of mRNA
at a volume
ratio of 2:1 (aqueous:ethanol) using a microfluidic mixer (NanoAssemblr0;
Precision
Nanosystems, Vancouver, BC) and flow rates of 18m1/min. Similarly, LNP
formulations can
be obtained using citrate or acetate buffered mRNA solutions (pH 3-4) and a
slightly differing
mixing ratio of 3:1 (v/v; aqueous:ethanol) and flow rates of 12m1/min.
88
CA 03108670 2021-02-03
WO 2020/030672 PCT/EP2019/071173
[00417] After the mixing process, the formulations are dialyzed against
10mM HEPES
or TRIS buffered isotonic Sucrose solution using 3.5 K MWCO Slide-A-Lyzer
Dialysis
Cassettes (Thermo Fisher Scientific) for at least 18 hours at 4 C. Instead of
Sucrose, other
sugars like Trehalose or Glucose can be equally used within the formulation
process.
[00418] Subsequently, the formulations are tested for particle size
(Zetasizer Nano ZS
instrument (Malvern Instruments Ltd, Malvern, UK), RNA encapsulation (Quant-iT
RiboGreen
RNA Assay Kit following manufacturer's (Thermo Fisher Scientific) protocol),
and endotoxin
and are found to be between 30 to 100 nm in size with a Zeta-potential of
>25mV, display
greater than 90% mRNA encapsulation and < 1 EU/ml of endotoxin.
[00419] mRNA-LNP formulations are stored at -80 C at a concentration of
RNA of ¨
0.3 jug/ 1 and an RNA to total lipid ratio of ¨ 0.03-0.05 (wt/wt) until
further in vitro or in vivo
use.
[00420] The features of the present invention disclosed in the specification,
the claims and/or
the drawings may both separately and in any combination thereof be material
for realizing the
invention in various forms thereof.
89
